| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | phosphotransferase activity, alcohol group as acceptor | CRIM1 CSNK1A1 CSNK2A1 MAP3K20 RIOK3 PPP1R9B PIP4K2C CSNK2A3 MUSK CASK | 1.74e-05 | 709 | 54 | 10 | GO:0016773 |
| GeneOntologyMolecularFunction | protein kinase activity | CRIM1 CSNK1A1 CSNK2A1 MAP3K20 RIOK3 PPP1R9B CSNK2A3 MUSK CASK | 2.99e-05 | 600 | 54 | 9 | GO:0004672 |
| GeneOntologyMolecularFunction | kinase activity | CRIM1 CSNK1A1 CSNK2A1 MAP3K20 RIOK3 PPP1R9B PIP4K2C CSNK2A3 MUSK CASK | 3.30e-05 | 764 | 54 | 10 | GO:0016301 |
| GeneOntologyMolecularFunction | transferase activity, transferring phosphorus-containing groups | CRIM1 CSNK1A1 CSNK2A1 PARP2 MAP3K20 RIOK3 PPP1R9B PIP4K2C CSNK2A3 MUSK CASK | 3.47e-05 | 938 | 54 | 11 | GO:0016772 |
| GeneOntologyMolecularFunction | actin filament binding | 3.65e-04 | 227 | 54 | 5 | GO:0051015 | |
| GeneOntologyMolecularFunction | protein serine kinase activity | 4.29e-04 | 363 | 54 | 6 | GO:0106310 | |
| GeneOntologyMolecularFunction | G protein activity | 5.46e-04 | 59 | 54 | 3 | GO:0003925 | |
| GeneOntologyMolecularFunction | protein serine/threonine kinase activity | 1.25e-03 | 446 | 54 | 6 | GO:0004674 | |
| GeneOntologyMolecularFunction | actin binding | 1.80e-03 | 479 | 54 | 6 | GO:0003779 | |
| GeneOntologyMolecularFunction | cysteine-type peptidase activity | 1.80e-03 | 192 | 54 | 4 | GO:0008234 | |
| GeneOntologyMolecularFunction | protein phosphatase regulator activity | 2.51e-03 | 100 | 54 | 3 | GO:0019888 | |
| GeneOntologyMolecularFunction | GDP binding | 2.73e-03 | 103 | 54 | 3 | GO:0019003 | |
| GeneOntologyBiologicalProcess | positive regulation of protein localization to membrane | 1.71e-05 | 130 | 51 | 5 | GO:1905477 | |
| GeneOntologyBiologicalProcess | actin filament depolymerization | 2.13e-05 | 66 | 51 | 4 | GO:0030042 | |
| GeneOntologyBiologicalProcess | regulation of protein localization to membrane | 2.52e-05 | 237 | 51 | 6 | GO:1905475 | |
| GeneOntologyBiologicalProcess | protein depolymerization | 2.81e-05 | 144 | 51 | 5 | GO:0051261 | |
| GeneOntologyBiologicalProcess | small GTPase-mediated signal transduction | 4.83e-05 | 538 | 51 | 8 | GO:0007264 | |
| GeneOntologyBiologicalProcess | negative regulation of protein depolymerization | 6.93e-05 | 89 | 51 | 4 | GO:1901880 | |
| GeneOntologyBiologicalProcess | positive regulation of small GTPase mediated signal transduction | 7.89e-05 | 92 | 51 | 4 | GO:0051057 | |
| GeneOntologyBiologicalProcess | positive regulation of protein localization | 9.31e-05 | 591 | 51 | 8 | GO:1903829 | |
| GeneOntologyBiologicalProcess | negative regulation of protein-containing complex disassembly | 1.09e-04 | 100 | 51 | 4 | GO:0043242 | |
| GeneOntologyBiologicalProcess | defense response to protozoan | 1.22e-04 | 39 | 51 | 3 | GO:0042832 | |
| GeneOntologyBiologicalProcess | enzyme-linked receptor protein signaling pathway | KRAS LGMN CYFIP1 CRIM1 SUDS3 SPTBN1 HRAS PIP4K2C USP9Y MUSK SVEP1 | 1.23e-04 | 1186 | 51 | 11 | GO:0007167 |
| GeneOntologyBiologicalProcess | regulation of cellular component biogenesis | CYFIP1 CSNK1A1 SPTBN1 HRAS RIOK3 PPP1R9B PIP4K2C ECT2 CNOT1 MUSK ADD2 | 1.26e-04 | 1189 | 51 | 11 | GO:0044087 |
| GeneOntologyBiologicalProcess | regulation of protein depolymerization | 1.32e-04 | 105 | 51 | 4 | GO:1901879 | |
| GeneOntologyBiologicalProcess | actin cytoskeleton organization | 1.38e-04 | 803 | 51 | 9 | GO:0030036 | |
| GeneOntologyBiologicalProcess | response to protozoan | 1.53e-04 | 42 | 51 | 3 | GO:0001562 | |
| GeneOntologyBiologicalProcess | ruffle assembly | 2.14e-04 | 47 | 51 | 3 | GO:0097178 | |
| GeneOntologyBiologicalProcess | actin polymerization or depolymerization | 2.17e-04 | 222 | 51 | 5 | GO:0008154 | |
| GeneOntologyBiologicalProcess | negative regulation of translation | 2.55e-04 | 230 | 51 | 5 | GO:0017148 | |
| GeneOntologyBiologicalProcess | Ras protein signal transduction | 2.82e-04 | 128 | 51 | 4 | GO:0007265 | |
| GeneOntologyBiologicalProcess | cell division | 2.88e-04 | 697 | 51 | 8 | GO:0051301 | |
| GeneOntologyBiologicalProcess | negative regulation of actin filament depolymerization | 2.89e-04 | 52 | 51 | 3 | GO:0030835 | |
| GeneOntologyBiologicalProcess | protein localization to membrane | 3.11e-04 | 705 | 51 | 8 | GO:0072657 | |
| GeneOntologyBiologicalProcess | actin filament-based process | 3.55e-04 | 912 | 51 | 9 | GO:0030029 | |
| GeneOntologyBiologicalProcess | regulation of actin cytoskeleton organization | 3.56e-04 | 384 | 51 | 6 | GO:0032956 | |
| GeneOntologyBiologicalProcess | regulation of organelle organization | CYFIP1 MAP1A SPTBN1 MAP3K20 HRAS SPECC1L STOX1 PIP4K2C ECT2 CNOT1 ADD2 | 3.61e-04 | 1342 | 51 | 11 | GO:0033043 |
| GeneOntologyBiologicalProcess | negative regulation of cytoplasmic pattern recognition receptor signaling pathway | 3.99e-04 | 58 | 51 | 3 | GO:0039532 | |
| GeneOntologyBiologicalProcess | insulin-like growth factor receptor signaling pathway | 4.41e-04 | 60 | 51 | 3 | GO:0048009 | |
| GeneOntologyBiologicalProcess | Rac protein signal transduction | 4.41e-04 | 60 | 51 | 3 | GO:0016601 | |
| GeneOntologyBiologicalProcess | regulation of protein-containing complex disassembly | 4.41e-04 | 144 | 51 | 4 | GO:0043244 | |
| GeneOntologyBiologicalProcess | cell surface receptor protein tyrosine kinase signaling pathway | 4.57e-04 | 747 | 51 | 8 | GO:0007169 | |
| GeneOntologyBiologicalProcess | regulation of actin filament depolymerization | 4.63e-04 | 61 | 51 | 3 | GO:0030834 | |
| GeneOntologyBiologicalProcess | negative regulation of ubiquitin-dependent protein catabolic process | 4.63e-04 | 61 | 51 | 3 | GO:2000059 | |
| GeneOntologyBiologicalProcess | ruffle organization | 4.63e-04 | 61 | 51 | 3 | GO:0031529 | |
| GeneOntologyBiologicalProcess | regulation of cytoskeleton organization | 5.25e-04 | 579 | 51 | 7 | GO:0051493 | |
| GeneOntologyBiologicalProcess | cell junction organization | 5.72e-04 | 974 | 51 | 9 | GO:0034330 | |
| GeneOntologyBiologicalProcess | protein localization to cell periphery | 5.85e-04 | 422 | 51 | 6 | GO:1990778 | |
| GeneOntologyBiologicalProcess | cognition | 5.93e-04 | 423 | 51 | 6 | GO:0050890 | |
| GeneOntologyBiologicalProcess | positive regulation of ruffle assembly | 6.17e-04 | 15 | 51 | 2 | GO:1900029 | |
| GeneOntologyBiologicalProcess | regulation of cellular localization | MAP1A CSNK2A1 SPTBN1 HRAS PPP1R9B MTCL1 ECT2 AKAP8L MUSK CASK | 6.64e-04 | 1212 | 51 | 10 | GO:0060341 |
| GeneOntologyBiologicalProcess | localization within membrane | 7.06e-04 | 798 | 51 | 8 | GO:0051668 | |
| GeneOntologyBiologicalProcess | regulation of actin filament-based process | 7.11e-04 | 438 | 51 | 6 | GO:0032970 | |
| GeneOntologyBiologicalProcess | protein-containing complex disassembly | 7.46e-04 | 291 | 51 | 5 | GO:0032984 | |
| GeneOntologyBiologicalProcess | regulation of synaptic plasticity | 7.70e-04 | 293 | 51 | 5 | GO:0048167 | |
| GeneOntologyBiologicalProcess | activation of immune response | 8.10e-04 | 623 | 51 | 7 | GO:0002253 | |
| GeneOntologyBiologicalProcess | regulation of protein localization to cell periphery | 8.41e-04 | 171 | 51 | 4 | GO:1904375 | |
| GeneOntologyBiologicalProcess | regulation of cell cycle | LGMN NRAS EP400 CSNK2A1 MAP3K20 HRAS PPP1R9B STOX1 ECT2 CSNK2A3 | 8.74e-04 | 1256 | 51 | 10 | GO:0051726 |
| GeneOntologyBiologicalProcess | negative regulation of protein-containing complex assembly | 8.78e-04 | 173 | 51 | 4 | GO:0031333 | |
| GeneOntologyBiologicalProcess | cellular response to ionizing radiation | 8.82e-04 | 76 | 51 | 3 | GO:0071479 | |
| GeneOntologyBiologicalProcess | positive regulation of Rac protein signal transduction | 8.94e-04 | 18 | 51 | 2 | GO:0035022 | |
| GeneOntologyBiologicalProcess | peptidyl-serine phosphorylation | 9.48e-04 | 307 | 51 | 5 | GO:0018105 | |
| GeneOntologyBiologicalProcess | regulation of actin polymerization or depolymerization | 9.56e-04 | 177 | 51 | 4 | GO:0008064 | |
| GeneOntologyBiologicalProcess | chromosome segregation | 9.70e-04 | 465 | 51 | 6 | GO:0007059 | |
| GeneOntologyBiologicalProcess | negative regulation of proteolysis involved in protein catabolic process | 9.87e-04 | 79 | 51 | 3 | GO:1903051 | |
| GeneOntologyBiologicalProcess | regulation of actin filament length | 1.02e-03 | 180 | 51 | 4 | GO:0030832 | |
| GeneOntologyBiologicalProcess | peptidyl-serine modification | 1.12e-03 | 319 | 51 | 5 | GO:0018209 | |
| GeneOntologyBiologicalProcess | regulation of ubiquitin-dependent protein catabolic process | 1.13e-03 | 185 | 51 | 4 | GO:2000058 | |
| GeneOntologyBiologicalProcess | modulation of chemical synaptic transmission | 1.16e-03 | 663 | 51 | 7 | GO:0050804 | |
| GeneOntologyBiologicalProcess | regulation of trans-synaptic signaling | 1.17e-03 | 664 | 51 | 7 | GO:0099177 | |
| GeneOntologyBiologicalProcess | regulation of protein localization | 1.25e-03 | 1087 | 51 | 9 | GO:0032880 | |
| GeneOntologyBiologicalProcess | regulation of translation | 1.32e-03 | 494 | 51 | 6 | GO:0006417 | |
| GeneOntologyBiologicalProcess | negative regulation of cytoskeleton organization | 1.34e-03 | 194 | 51 | 4 | GO:0051494 | |
| GeneOntologyBiologicalProcess | regulation of small GTPase mediated signal transduction | 1.36e-03 | 333 | 51 | 5 | GO:0051056 | |
| GeneOntologyBiologicalProcess | negative regulation of supramolecular fiber organization | 1.42e-03 | 197 | 51 | 4 | GO:1902904 | |
| GeneOntologyBiologicalProcess | positive regulation of growth | 1.47e-03 | 339 | 51 | 5 | GO:0045927 | |
| GeneOntologyBiologicalProcess | actin filament organization | 1.54e-03 | 509 | 51 | 6 | GO:0007015 | |
| GeneOntologyBiologicalProcess | mitotic cytokinesis | 1.68e-03 | 95 | 51 | 3 | GO:0000281 | |
| GeneOntologyBiologicalProcess | learning | 1.86e-03 | 212 | 51 | 4 | GO:0007612 | |
| GeneOntologyBiologicalProcess | positive regulation of cell growth | 1.89e-03 | 213 | 51 | 4 | GO:0030307 | |
| GeneOntologyBiologicalProcess | anterograde trans-synaptic signaling | 1.90e-03 | 931 | 51 | 8 | GO:0098916 | |
| GeneOntologyBiologicalProcess | chemical synaptic transmission | 1.90e-03 | 931 | 51 | 8 | GO:0007268 | |
| GeneOntologyBiologicalProcess | trans-synaptic signaling | 2.00e-03 | 939 | 51 | 8 | GO:0099537 | |
| GeneOntologyCellularComponent | protein kinase CK2 complex | 3.92e-05 | 4 | 54 | 2 | GO:0005956 | |
| GeneOntologyCellularComponent | cell cortex | 3.78e-04 | 371 | 54 | 6 | GO:0005938 | |
| GeneOntologyCellularComponent | CCR4-NOT complex | 7.68e-04 | 16 | 54 | 2 | GO:0030014 | |
| GeneOntologyCellularComponent | intracellular protein-containing complex | 7.90e-04 | 972 | 54 | 9 | GO:0140535 | |
| GeneOntologyCellularComponent | anchoring junction | 8.13e-04 | 976 | 54 | 9 | GO:0070161 | |
| GeneOntologyCellularComponent | postsynaptic density | 1.05e-03 | 451 | 54 | 6 | GO:0014069 | |
| GeneOntologyCellularComponent | histone deacetylase complex | 1.39e-03 | 85 | 54 | 3 | GO:0000118 | |
| GeneOntologyCellularComponent | asymmetric synapse | 1.40e-03 | 477 | 54 | 6 | GO:0032279 | |
| GeneOntologyCellularComponent | Sin3-type complex | 1.46e-03 | 22 | 54 | 2 | GO:0070822 | |
| HumanPheno | Linear nevus sebaceous | 1.65e-08 | 3 | 14 | 3 | HP:0010817 | |
| HumanPheno | Nevus sebaceous | 1.65e-07 | 5 | 14 | 3 | HP:0010815 | |
| HumanPheno | Abnormal palate morphology | KRAS NRAS CSNK2A1 DHCR24 SPTBN1 MAP3K20 HRAS SPECC1L CNOT1 RPL5 MUSK CASK | 1.60e-06 | 1202 | 14 | 12 | HP:0000174 |
| HumanPheno | Epidermal nevus | 3.58e-06 | 12 | 14 | 3 | HP:0010816 | |
| HumanPheno | Abnormal nasal bridge morphology | KRAS NRAS CSNK2A1 DHCR24 SPTBN1 HRAS SPECC1L CNOT1 RPL5 MUSK CASK | 4.34e-06 | 1029 | 14 | 11 | HP:0000422 |
| HumanPheno | High palate | 4.42e-06 | 794 | 14 | 10 | HP:0000218 | |
| HumanPheno | Depressed nasal bridge | 5.64e-06 | 612 | 14 | 9 | HP:0005280 | |
| HumanPheno | Flattened nasal bridge | 5.64e-06 | 612 | 14 | 9 | HP:0000425 | |
| HumanPheno | Hemimegalencephaly | 5.91e-06 | 14 | 14 | 3 | HP:0007206 | |
| HumanPheno | Abnormal dermatoglyphics | 7.46e-06 | 314 | 14 | 7 | HP:0007477 | |
| HumanPheno | Micrognathia | KRAS NRAS CSNK2A1 DHCR24 MAP3K20 HRAS SPECC1L RPL5 MUSK CASK | 7.75e-06 | 843 | 14 | 10 | HP:0000347 |
| HumanPheno | Aplasia/Hypoplasia of the mandible | KRAS NRAS CSNK2A1 DHCR24 MAP3K20 HRAS SPECC1L RPL5 MUSK CASK | 7.92e-06 | 845 | 14 | 10 | HP:0009118 |
| HumanPheno | Short nose | 9.38e-06 | 325 | 14 | 7 | HP:0003196 | |
| HumanPheno | Abnormalities of placenta or umbilical cord | 9.96e-06 | 117 | 14 | 5 | HP:0001194 | |
| HumanPheno | Sarcoma | 1.04e-05 | 210 | 14 | 6 | HP:0100242 | |
| HumanPheno | Cranial asymmetry | 1.10e-05 | 17 | 14 | 3 | HP:0000267 | |
| HumanPheno | Brachydactyly | 1.21e-05 | 670 | 14 | 9 | HP:0001156 | |
| HumanPheno | Round face | 1.22e-05 | 122 | 14 | 5 | HP:0000311 | |
| HumanPheno | Short digit | 1.24e-05 | 672 | 14 | 9 | HP:0011927 | |
| HumanPheno | Fibroma | 1.32e-05 | 124 | 14 | 5 | HP:0010614 | |
| HumanPheno | Fibrous tissue neoplasm | 1.43e-05 | 126 | 14 | 5 | HP:0012316 | |
| HumanPheno | Abnormality of prenatal development or birth | KRAS NRAS CSNK2A1 SPTBN1 MAP3K20 HRAS SPECC1L STOX1 CNOT1 RPL5 MUSK | 1.48e-05 | 1159 | 14 | 11 | HP:0001197 |
| HumanPheno | Aplasia/Hypoplasia involving bones of the skull | KRAS NRAS CSNK2A1 DHCR24 MAP3K20 HRAS SPECC1L RPL5 MUSK CASK | 1.66e-05 | 915 | 14 | 10 | HP:0009116 |
| HumanPheno | Abnormal external nose morphology | KRAS NRAS CSNK2A1 DHCR24 SPTBN1 HRAS SPECC1L CNOT1 MUSK CASK | 1.68e-05 | 916 | 14 | 10 | HP:0010938 |
| HumanPheno | Prominent occiput | 1.82e-05 | 62 | 14 | 4 | HP:0000269 | |
| HumanPheno | Nevus spilus | 2.10e-05 | 3 | 14 | 2 | HP:0025510 | |
| HumanPheno | Melanocytic nevus | 2.63e-05 | 68 | 14 | 4 | HP:0000995 | |
| HumanPheno | Absent septum pellucidum | 2.79e-05 | 69 | 14 | 4 | HP:0001331 | |
| HumanPheno | Abnormal upper lip morphology | 3.13e-05 | 980 | 14 | 10 | HP:0000177 | |
| HumanPheno | Anteverted nares | 3.30e-05 | 559 | 14 | 8 | HP:0000463 | |
| HumanPheno | Upturned nose | 3.30e-05 | 559 | 14 | 8 | HP:0000427 | |
| HumanPheno | Low-set ears | 3.50e-05 | 761 | 14 | 9 | HP:0000369 | |
| HumanPheno | Abnormality of the palmar creases | 3.54e-05 | 260 | 14 | 6 | HP:0010490 | |
| HumanPheno | Hemihypertrophy | 3.67e-05 | 25 | 14 | 3 | HP:0001528 | |
| HumanPheno | Adenoma sebaceum | 3.67e-05 | 25 | 14 | 3 | HP:0009720 | |
| HumanPheno | Hypophosphatemic rickets | 3.67e-05 | 25 | 14 | 3 | HP:0004912 | |
| HumanPheno | Aplasia/Hypoplasia involving the nose | 3.75e-05 | 401 | 14 | 7 | HP:0009924 | |
| HumanPheno | Abnormal palmar dermatoglyphics | 3.95e-05 | 265 | 14 | 6 | HP:0001018 | |
| HumanPheno | Aplasia/hypoplasia affecting bones of the axial skeleton | KRAS NRAS CSNK2A1 DHCR24 MAP3K20 HRAS SPECC1L RPL5 MUSK CASK | 4.06e-05 | 1008 | 14 | 10 | HP:0009122 |
| HumanPheno | Abnormal nostril morphology | 4.06e-05 | 575 | 14 | 8 | HP:0005288 | |
| HumanPheno | Abnormal pinna morphology | KRAS NRAS CSNK2A1 DHCR24 SPTBN1 HRAS SPECC1L CNOT1 RPL5 MUSK CASK | 4.74e-05 | 1299 | 14 | 11 | HP:0000377 |
| HumanPheno | Coloboma | 4.78e-05 | 274 | 14 | 6 | HP:0000589 | |
| HumanPheno | Sleep abnormality | 5.29e-05 | 596 | 14 | 8 | HP:0002360 | |
| HumanPheno | Abnormal fourth ventricle morphology | 5.30e-05 | 165 | 14 | 5 | HP:0010950 | |
| HumanPheno | Dilated fourth ventricle | 5.30e-05 | 165 | 14 | 5 | HP:0002198 | |
| HumanPheno | Soft tissue sarcoma | 5.46e-05 | 166 | 14 | 5 | HP:0030448 | |
| HumanPheno | Long philtrum | 5.83e-05 | 429 | 14 | 7 | HP:0000343 | |
| HumanPheno | Abnormal male external genitalia morphology | KRAS NRAS CSNK2A1 DHCR24 SPTBN1 HRAS SPECC1L USP9Y RPL5 MUSK CASK | 5.97e-05 | 1329 | 14 | 11 | HP:0000032 |
| HumanPheno | Abnormality of the outer ear | KRAS NRAS CSNK2A1 DHCR24 SPTBN1 HRAS SPECC1L CNOT1 RPL5 MUSK CASK | 6.35e-05 | 1337 | 14 | 11 | HP:0000356 |
| HumanPheno | Angiofibromas | 6.42e-05 | 30 | 14 | 3 | HP:0010615 | |
| HumanPheno | Hyperphosphaturia | 6.42e-05 | 30 | 14 | 3 | HP:0003109 | |
| HumanPheno | Deep palmar crease | 6.42e-05 | 30 | 14 | 3 | HP:0006191 | |
| HumanPheno | Epicanthus | 6.58e-05 | 614 | 14 | 8 | HP:0000286 | |
| HumanPheno | Telecanthus | 6.66e-05 | 173 | 14 | 5 | HP:0000506 | |
| HumanPheno | Hypoplastic nasal bridge | 6.98e-05 | 5 | 14 | 2 | HP:0005281 | |
| HumanPheno | Cavernous hemangioma | 7.10e-05 | 31 | 14 | 3 | HP:0001048 | |
| HumanPheno | Transitional cell carcinoma of the bladder | 7.10e-05 | 31 | 14 | 3 | HP:0006740 | |
| HumanPheno | Hypertelorism | 7.15e-05 | 830 | 14 | 9 | HP:0000316 | |
| HumanPheno | Abnormal hand morphology | 7.75e-05 | 1082 | 14 | 10 | HP:0005922 | |
| HumanPheno | Porencephalic cyst | 7.82e-05 | 32 | 14 | 3 | HP:0002132 | |
| HumanPheno | Abnormal external genitalia | KRAS NRAS CSNK2A1 DHCR24 SPTBN1 HRAS SPECC1L USP9Y RPL5 MUSK CASK | 8.23e-05 | 1372 | 14 | 11 | HP:0000811 |
| HumanPheno | Abnormal morphology of the vestibule of the inner ear | 8.59e-05 | 33 | 14 | 3 | HP:0011376 | |
| HumanPheno | Bladder carcinoma | 8.59e-05 | 33 | 14 | 3 | HP:0002862 | |
| HumanPheno | Abnormal morphology of the nasal alae | 8.81e-05 | 639 | 14 | 8 | HP:0000429 | |
| HumanPheno | Abnormal finger morphology | KRAS NRAS CSNK2A1 SPTBN1 MAP3K20 HRAS SPECC1L CNOT1 RPL5 MUSK CASK | 9.05e-05 | 1385 | 14 | 11 | HP:0001167 |
| HumanPheno | Genu recurvatum | 9.41e-05 | 34 | 14 | 3 | HP:0002816 | |
| HumanPheno | Abnormality of dental color | 9.41e-05 | 34 | 14 | 3 | HP:0011073 | |
| HumanPheno | Bladder neoplasm | 9.41e-05 | 34 | 14 | 3 | HP:0009725 | |
| HumanPheno | Abnormal fetal morphology | 9.58e-05 | 310 | 14 | 6 | HP:0034058 | |
| HumanPheno | Polyhydramnios | 9.94e-05 | 312 | 14 | 6 | HP:0001561 | |
| HumanPheno | Abnormal urine phosphate concentration | 1.03e-04 | 35 | 14 | 3 | HP:0012599 | |
| HumanPheno | Abnormal mandible morphology | KRAS NRAS CSNK2A1 DHCR24 MAP3K20 HRAS SPECC1L RPL5 MUSK CASK | 1.04e-04 | 1118 | 14 | 10 | HP:0000277 |
| HumanPheno | Abnormal lymphocyte apoptosis | 1.05e-04 | 6 | 14 | 2 | HP:0030886 | |
| HumanPheno | Non-medullary thyroid carcinoma | 1.05e-04 | 6 | 14 | 2 | HP:0040198 | |
| HumanPheno | Decreased lymphocyte apoptosis | 1.05e-04 | 6 | 14 | 2 | HP:0002731 | |
| HumanPheno | Abnormal eyelid morphology | KRAS NRAS CSNK2A1 DHCR24 SPTBN1 HRAS SPECC1L CNOT1 RPL5 MUSK CASK | 1.07e-04 | 1408 | 14 | 11 | HP:0000492 |
| HumanPheno | Abnormality of globe location | 1.08e-04 | 1122 | 14 | 10 | HP:0100886 | |
| HumanPheno | Curly hair | 1.12e-04 | 36 | 14 | 3 | HP:0002212 | |
| HumanPheno | Abnormality of the male genitalia | KRAS NRAS CSNK2A1 DHCR24 SPTBN1 HRAS SPECC1L USP9Y RPL5 MUSK CASK | 1.31e-04 | 1437 | 14 | 11 | HP:0010461 |
| HumanPheno | Sporadic | 1.35e-04 | 103 | 14 | 4 | HP:0003745 | |
| HumanPheno | Abnormal placenta morphology | 1.43e-04 | 39 | 14 | 3 | HP:0100767 | |
| HumanPheno | Congenital giant melanocytic nevus | 1.46e-04 | 7 | 14 | 2 | HP:0005600 | |
| HumanPheno | Prominence of the premaxilla | 1.46e-04 | 7 | 14 | 2 | HP:0010759 | |
| HumanPheno | Broad forehead | 1.50e-04 | 205 | 14 | 5 | HP:0000337 | |
| HumanPheno | Hyperextensibility of the knee | 1.54e-04 | 40 | 14 | 3 | HP:0010500 | |
| HumanPheno | Plagiocephaly | 1.60e-04 | 208 | 14 | 5 | HP:0001357 | |
| HumanPheno | Abnormality of the jaws | KRAS NRAS CSNK2A1 DHCR24 MAP3K20 HRAS SPECC1L RPL5 MUSK CASK | 1.63e-04 | 1175 | 14 | 10 | HP:0000209 |
| HumanPheno | Abnormal jaw morphology | KRAS NRAS CSNK2A1 DHCR24 MAP3K20 HRAS SPECC1L RPL5 MUSK CASK | 1.65e-04 | 1176 | 14 | 10 | HP:0030791 |
| HumanPheno | Wide nasal bridge | 1.73e-04 | 508 | 14 | 7 | HP:0000431 | |
| HumanPheno | Fetal neck anomaly | 1.81e-04 | 111 | 14 | 4 | HP:0025667 | |
| HumanPheno | Abnormal septum pellucidum morphology | 1.87e-04 | 112 | 14 | 4 | HP:0007375 | |
| HumanPheno | Megalencephaly | 2.05e-04 | 44 | 14 | 3 | HP:0001355 | |
| HumanPheno | Abnormal location of ears | 2.05e-04 | 945 | 14 | 9 | HP:0000357 | |
| HumanPheno | Abnormality of the philtrum | 2.22e-04 | 726 | 14 | 8 | HP:0000288 | |
| HumanPheno | Abnormal aortic morphology | 2.31e-04 | 363 | 14 | 6 | HP:0030963 | |
| HumanPheno | Abnormal shape of the occiput | 2.36e-04 | 119 | 14 | 4 | HP:0011217 | |
| HumanPheno | Abnormal urine anion concentration | 2.50e-04 | 47 | 14 | 3 | HP:0011866 | |
| HumanPheno | Rickets | 2.50e-04 | 47 | 14 | 3 | HP:0002748 | |
| HumanPheno | Abnormal occipital bone morphology | 2.52e-04 | 121 | 14 | 4 | HP:0012294 | |
| HumanPheno | Regional abnormality of skin | 2.58e-04 | 541 | 14 | 7 | HP:0011356 | |
| MousePheno | hypertension | 2.54e-05 | 56 | 43 | 4 | MP:0000231 | |
| Domain | RAS | 1.40e-04 | 35 | 54 | 3 | PS51421 | |
| Domain | Small_GTPase_Ras | 1.66e-04 | 37 | 54 | 3 | IPR020849 | |
| Domain | Prot_kinase_dom | 4.94e-04 | 489 | 54 | 7 | IPR000719 | |
| Domain | PROTEIN_KINASE_DOM | 5.18e-04 | 493 | 54 | 7 | PS50011 | |
| Domain | Kinase-like_dom | 9.06e-04 | 542 | 54 | 7 | IPR011009 | |
| Domain | PROTEIN_KINASE_ATP | 2.03e-03 | 459 | 54 | 6 | PS00107 | |
| Domain | Ser/Thr_kinase_AS | 3.64e-03 | 357 | 54 | 5 | IPR008271 | |
| Domain | S_TKc | 3.73e-03 | 359 | 54 | 5 | SM00220 | |
| Domain | PROTEIN_KINASE_ST | 3.86e-03 | 362 | 54 | 5 | PS00108 | |
| Domain | Ras | 7.14e-03 | 136 | 54 | 3 | PF00071 | |
| Domain | PDZ | 7.89e-03 | 141 | 54 | 3 | PF00595 | |
| Domain | PDZ | 9.00e-03 | 148 | 54 | 3 | SM00228 | |
| Domain | - | 9.34e-03 | 150 | 54 | 3 | 2.30.42.10 | |
| Domain | PDZ | 9.51e-03 | 151 | 54 | 3 | PS50106 | |
| Domain | PDZ | 9.68e-03 | 152 | 54 | 3 | IPR001478 | |
| Domain | Small_GTPase | 1.11e-02 | 160 | 54 | 3 | IPR001806 | |
| Pathway | KEGG_TIGHT_JUNCTION | 7.75e-08 | 132 | 40 | 7 | M11355 | |
| Pathway | REACTOME_SIGNALING_BY_FLT3_FUSION_PROTEINS | 2.09e-07 | 19 | 40 | 4 | M41732 | |
| Pathway | REACTOME_ACTIVATION_OF_RAS_IN_B_CELLS | 2.11e-07 | 5 | 40 | 3 | M26921 | |
| Pathway | REACTOME_ESTROGEN_STIMULATED_SIGNALING_THROUGH_PRKCZ | 4.21e-07 | 6 | 40 | 3 | M27951 | |
| Pathway | KEGG_MEDICUS_VARIANT_LOSS_OF_RASSF1_TO_RAS_RASSF1_SIGNALING_PATHWAY | 4.21e-07 | 6 | 40 | 3 | M47433 | |
| Pathway | KEGG_MEDICUS_REFERENCE_REGULATION_OF_GF_RTK_RAS_ERK_SIGNALING_RAS_UBIQUITINATION_BY_CUL3_COMPLEX | 4.21e-07 | 6 | 40 | 3 | M47931 | |
| Pathway | KEGG_MEDICUS_REFERENCE_REGULATION_OF_GF_RTK_RAS_ERK_SIGNALING_SPRED_AND_NF1 | 4.21e-07 | 6 | 40 | 3 | M47932 | |
| Pathway | REACTOME_RAS_SIGNALING_DOWNSTREAM_OF_NF1_LOSS_OF_FUNCTION_VARIANTS | 7.35e-07 | 7 | 40 | 3 | M29717 | |
| Pathway | REACTOME_SOS_MEDIATED_SIGNALLING | 7.35e-07 | 7 | 40 | 3 | M19489 | |
| Pathway | REACTOME_FLT3_SIGNALING_IN_DISEASE | 1.08e-06 | 28 | 40 | 4 | M41724 | |
| Pathway | KEGG_MEDICUS_REFERENCE_REGULATION_OF_GF_RTK_RAS_ERK_SIGNALING_RASGAP | 1.17e-06 | 8 | 40 | 3 | M47935 | |
| Pathway | REACTOME_ACTIVATED_NTRK3_SIGNALS_THROUGH_RAS | 1.17e-06 | 8 | 40 | 3 | M27919 | |
| Pathway | KEGG_THYROID_CANCER | 1.25e-06 | 29 | 40 | 4 | M523 | |
| Pathway | REACTOME_EGFR_TRANSACTIVATION_BY_GASTRIN | 1.76e-06 | 9 | 40 | 3 | M27156 | |
| Pathway | REACTOME_SHC_RELATED_EVENTS_TRIGGERED_BY_IGF1R | 1.76e-06 | 9 | 40 | 3 | M27173 | |
| Pathway | REACTOME_ACTIVATED_NTRK2_SIGNALS_THROUGH_RAS | 1.76e-06 | 9 | 40 | 3 | M27904 | |
| Pathway | REACTOME_MET_ACTIVATES_RAS_SIGNALING | 3.44e-06 | 11 | 40 | 3 | M27740 | |
| Pathway | REACTOME_SIGNALING_BY_FGFR4_IN_DISEASE | 3.44e-06 | 11 | 40 | 3 | M27535 | |
| Pathway | KEGG_MEDICUS_VARIANT_RET_FUSION_KINASE_TO_RAS_ERK_SIGNALING_PATHWAY | 3.44e-06 | 11 | 40 | 3 | M47370 | |
| Pathway | KEGG_MEDICUS_VARIANT_TRK_FUSION_KINASE_TO_RAS_ERK_SIGNALING_PATHWAY | 3.44e-06 | 11 | 40 | 3 | M47371 | |
| Pathway | REACTOME_CONSTITUTIVE_SIGNALING_BY_OVEREXPRESSED_ERBB2 | 3.44e-06 | 11 | 40 | 3 | M29814 | |
| Pathway | KEGG_MEDICUS_REFERENCE_EGF_EGFR_RAS_RALGDS_SIGNALING_PATHWAY | 3.44e-06 | 11 | 40 | 3 | M47436 | |
| Pathway | KEGG_MEDICUS_REFERENCE_EGF_EGFR_RAS_RASSF1_SIGNALING_PATHWAY | 3.44e-06 | 11 | 40 | 3 | M47432 | |
| Pathway | REACTOME_ACTIVATED_NTRK2_SIGNALS_THROUGH_FRS2_AND_FRS3 | 3.44e-06 | 11 | 40 | 3 | M27911 | |
| Pathway | WP_BREAST_CANCER_PATHWAY | 4.35e-06 | 154 | 40 | 6 | M39739 | |
| Pathway | KEGG_MEDICUS_VARIANT_EML4_ALK_FUSION_KINASE_TO_RAS_ERK_SIGNALING_PATHWAY | 4.57e-06 | 12 | 40 | 3 | M47369 | |
| Pathway | KEGG_MEDICUS_ENV_FACTOR_METALS_TO_RAS_ERK_SIGNALING_PATHWAY | 4.57e-06 | 12 | 40 | 3 | M47815 | |
| Pathway | REACTOME_SIGNALING_BY_PDGFRA_TRANSMEMBRANE_JUXTAMEMBRANE_AND_KINASE_DOMAIN_MUTANTS | 4.57e-06 | 12 | 40 | 3 | M29851 | |
| Pathway | WP_RALA_DOWNSTREAM_REGULATED_GENES | 4.57e-06 | 12 | 40 | 3 | M39408 | |
| Pathway | KEGG_MEDICUS_REFERENCE_EGF_EGFR_RAS_JNK_SIGNALING_PATHWAY | 5.94e-06 | 13 | 40 | 3 | M47594 | |
| Pathway | REACTOME_P38MAPK_EVENTS | 5.94e-06 | 13 | 40 | 3 | M1441 | |
| Pathway | REACTOME_PTK6_REGULATES_RHO_GTPASES_RAS_GTPASE_AND_MAP_KINASES | 7.54e-06 | 14 | 40 | 3 | M27734 | |
| Pathway | KEGG_MEDICUS_VARIANT_BCR_ABL_FUSION_KINASE_TO_RAS_ERK_SIGNALING_PATHWAY | 7.54e-06 | 14 | 40 | 3 | M47364 | |
| Pathway | KEGG_MEDICUS_VARIANT_MUTATION_ACTIVATED_KIT_TO_RAS_ERK_SIGNALING_PATHWAY | 7.54e-06 | 14 | 40 | 3 | M47365 | |
| Pathway | KEGG_MEDICUS_VARIANT_DUPLICATION_OR_MUTATION_ACTIVATED_FLT3_TO_RAS_ERK_SIGNALING_PATHWAY | 7.54e-06 | 14 | 40 | 3 | M47366 | |
| Pathway | KEGG_MEDICUS_VARIANT_DUPLICATION_OR_MUTATION_ACTIVATED_FLT3_TO_RAS_PI3K_SIGNALING_PATHWAY | 7.54e-06 | 14 | 40 | 3 | M47390 | |
| Pathway | KEGG_MEDICUS_VARIANT_AMPLIFIED_PDGFR_TO_RAS_ERK_SIGNALING_PATHWAY | 7.54e-06 | 14 | 40 | 3 | M47378 | |
| Pathway | REACTOME_SHC1_EVENTS_IN_ERBB4_SIGNALING | 7.54e-06 | 14 | 40 | 3 | M569 | |
| Pathway | PID_TCR_RAS_PATHWAY | 7.54e-06 | 14 | 40 | 3 | M134 | |
| Pathway | KEGG_MEDICUS_VARIANT_MET_OVEREXPRESSION_TO_RAS_ERK_SIGNALING_PATHWAY | 7.54e-06 | 14 | 40 | 3 | M47488 | |
| Pathway | REACTOME_ERYTHROPOIETIN_ACTIVATES_RAS | 7.54e-06 | 14 | 40 | 3 | M27908 | |
| Pathway | REACTOME_SHC1_EVENTS_IN_EGFR_SIGNALING | 7.54e-06 | 14 | 40 | 3 | M719 | |
| Pathway | REACTOME_CONSTITUTIVE_SIGNALING_BY_EGFRVIII | 9.41e-06 | 15 | 40 | 3 | M29701 | |
| Pathway | KEGG_MEDICUS_VARIANT_MUTATION_ACTIVATED_MET_TO_RAS_ERK_SIGNALING_PATHWAY | 9.41e-06 | 15 | 40 | 3 | M47367 | |
| Pathway | KEGG_MEDICUS_REFERENCE_EGF_EGFR_RAS_PI3K_SIGNALING_PATHWAY | 9.41e-06 | 15 | 40 | 3 | M47389 | |
| Pathway | KEGG_MEDICUS_VARIANT_MUTATION_ACTIVATED_EGFR_TO_RAS_ERK_SIGNALING_PATHWAY | 9.41e-06 | 15 | 40 | 3 | M47375 | |
| Pathway | KEGG_MEDICUS_VARIANT_AMPLIFIED_FGFR_TO_RAS_ERK_SIGNALING_PATHWAY | 9.41e-06 | 15 | 40 | 3 | M47380 | |
| Pathway | KEGG_MEDICUS_REFERENCE_CA2_PYK2_RAS_ERK_SIGNALING_PATHWAY | 9.41e-06 | 15 | 40 | 3 | M47592 | |
| Pathway | KEGG_MEDICUS_PATHOGEN_HBV_HBX_TO_RAS_ERK_SIGNALING_PATHWAY | 9.41e-06 | 15 | 40 | 3 | M47593 | |
| Pathway | KEGG_MEDICUS_VARIANT_MUTATION_INACTIVATED_FGF17_TO_RAS_ERK_SIGNALING_PATHWAY | 9.41e-06 | 15 | 40 | 3 | M47640 | |
| Pathway | KEGG_MEDICUS_VARIANT_IGF2_OVEREXPRESSION_TO_RAS_ERK_SIGNALING_PATHWAY | 9.41e-06 | 15 | 40 | 3 | M47485 | |
| Pathway | KEGG_MEDICUS_REFERENCE_HGF_MET_RAS_ERK_SIGNALING_PATHWAY | 9.41e-06 | 15 | 40 | 3 | M47473 | |
| Pathway | KEGG_MEDICUS_REFERENCE_FLT3LG_FLT3_RAS_ERK_SIGNALING_PATHWAY | 9.41e-06 | 15 | 40 | 3 | M47474 | |
| Pathway | KEGG_MEDICUS_REFERENCE_FLT3LG_FLT3_RAS_PI3K_SIGNALING_PATHWAY | 9.41e-06 | 15 | 40 | 3 | M47475 | |
| Pathway | KEGG_MEDICUS_REFERENCE_TGFA_EGFR_RAS_ERK_SIGNALING_PATHWAY | 9.41e-06 | 15 | 40 | 3 | M47480 | |
| Pathway | KEGG_MEDICUS_VARIANT_EGF_OVEREXPRESSION_TO_RAS_ERK_SIGNALING_PATHWAY | 9.41e-06 | 15 | 40 | 3 | M47495 | |
| Pathway | KEGG_MEDICUS_REFERENCE_EREG_EGFR_RAS_ERK_SIGNALING_PATHWAY | 9.41e-06 | 15 | 40 | 3 | M47496 | |
| Pathway | KEGG_MEDICUS_REFERENCE_AREG_EGFR_RAS_ERK_SIGNALING_PATHWAY | 9.41e-06 | 15 | 40 | 3 | M47497 | |
| Pathway | KEGG_MEDICUS_REFERENCE_KITLG_KIT_RAS_ERK_SIGNALING_PATHWAY | 9.41e-06 | 15 | 40 | 3 | M47472 | |
| Pathway | KEGG_MEDICUS_PATHOGEN_HCMV_GB_TO_PDGFR_RAS_ERK_SIGNALING_PATHWAY | 9.41e-06 | 15 | 40 | 3 | M47535 | |
| Pathway | KEGG_MEDICUS_PATHOGEN_HPV_E5_TO_EGFR_RAS_ERK_SIGNALING_PATHWAY | 9.41e-06 | 15 | 40 | 3 | M47531 | |
| Pathway | KEGG_MEDICUS_REFERENCE_EGF_EGFR_RAS_ERK_SIGNALING_PATHWAY | 1.16e-05 | 16 | 40 | 3 | M47363 | |
| Pathway | KEGG_MEDICUS_VARIANT_MUTATION_ACTIVATED_FGFR3_TO_RAS_ERK_SIGNALING_PATHWAY | 1.16e-05 | 16 | 40 | 3 | M47373 | |
| Pathway | KEGG_MEDICUS_REFERENCE_EGF_ERBB2_RAS_ERK_SIGNALING_PATHWAY | 1.16e-05 | 16 | 40 | 3 | M47381 | |
| Pathway | KEGG_MEDICUS_REFERENCE_P4_PR_RAS_ERK_SIGNALING_PATHWAY | 1.16e-05 | 16 | 40 | 3 | M47804 | |
| Pathway | KEGG_MEDICUS_ENV_FACTOR_E2_TO_RAS_ERK_SIGNALING_PATHWAY | 1.16e-05 | 16 | 40 | 3 | M47801 | |
| Pathway | REACTOME_GRB2_EVENTS_IN_ERBB2_SIGNALING | 1.16e-05 | 16 | 40 | 3 | M562 | |
| Pathway | REACTOME_SIGNALING_BY_ERBB2_ECD_MUTANTS | 1.16e-05 | 16 | 40 | 3 | M29847 | |
| Pathway | KEGG_MEDICUS_REFERENCE_IGF_IGF1R_RAS_ERK_SIGNALING_PATHWAY | 1.16e-05 | 16 | 40 | 3 | M47483 | |
| Pathway | REACTOME_SIGNALING_BY_FLT3_ITD_AND_TKD_MUTANTS | 1.16e-05 | 16 | 40 | 3 | M41733 | |
| Pathway | KEGG_MEDICUS_REFERENCE_AGE_RAGE_SIGNALING_PATHWAY | 1.16e-05 | 16 | 40 | 3 | M47682 | |
| Pathway | KEGG_MEDICUS_REFERENCE_PDGF_PDGFR_RAS_ERK_SIGNALING_PATHWAY | 1.40e-05 | 17 | 40 | 3 | M47376 | |
| Pathway | KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_ABETA_TO_AGE_RAGE_SIGNALING_PATHWAY | 1.40e-05 | 17 | 40 | 3 | M47684 | |
| Pathway | REACTOME_SIGNALING_BY_NTRK3_TRKC | 1.40e-05 | 17 | 40 | 3 | M27918 | |
| Pathway | REACTOME_SHC_MEDIATED_CASCADE_FGFR3 | 1.68e-05 | 18 | 40 | 3 | M27518 | |
| Pathway | WP_INHIBITION_OF_EXOSOME_BIOGENESIS_AND_SECRETION_BY_MANUMYCIN_A_IN_CRPC_CELLS | 1.68e-05 | 18 | 40 | 3 | M39737 | |
| Pathway | REACTOME_GASTRIN_CREB_SIGNALLING_PATHWAY_VIA_PKC_AND_MAPK | 1.68e-05 | 18 | 40 | 3 | M657 | |
| Pathway | REACTOME_TIE2_SIGNALING | 1.68e-05 | 18 | 40 | 3 | M11932 | |
| Pathway | KEGG_MEDICUS_ENV_FACTOR_NNK_NNN_TO_RAS_ERK_SIGNALING_PATHWAY | 1.99e-05 | 19 | 40 | 3 | M47793 | |
| Pathway | REACTOME_CONSTITUTIVE_SIGNALING_BY_LIGAND_RESPONSIVE_EGFR_CANCER_VARIANTS | 1.99e-05 | 19 | 40 | 3 | M559 | |
| Pathway | REACTOME_VEGFR2_MEDIATED_CELL_PROLIFERATION | 1.99e-05 | 19 | 40 | 3 | M27423 | |
| Pathway | REACTOME_SIGNALLING_TO_RAS | 2.33e-05 | 20 | 40 | 3 | M12256 | |
| Pathway | REACTOME_FRS_MEDIATED_FGFR3_SIGNALING | 2.33e-05 | 20 | 40 | 3 | M27519 | |
| Pathway | REACTOME_SHC_MEDIATED_CASCADE_FGFR4 | 2.33e-05 | 20 | 40 | 3 | M27524 | |
| Pathway | WP_SEROTONIN_RECEPTOR_2_AND_ELKSRFGATA4_SIGNALING | 2.33e-05 | 20 | 40 | 3 | M39485 | |
| Pathway | REACTOME_SIGNALING_BY_PDGFR_IN_DISEASE | 2.33e-05 | 20 | 40 | 3 | M29849 | |
| Pathway | REACTOME_RAS_ACTIVATION_UPON_CA2_INFLUX_THROUGH_NMDA_RECEPTOR | 2.33e-05 | 20 | 40 | 3 | M17670 | |
| Pathway | REACTOME_SIGNALING_BY_KIT_IN_DISEASE | 2.33e-05 | 20 | 40 | 3 | M39002 | |
| Pathway | REACTOME_SHC_MEDIATED_CASCADE_FGFR1 | 2.72e-05 | 21 | 40 | 3 | M27511 | |
| Pathway | KEGG_MEDICUS_REFERENCE_ACH_CHRN_RAS_ERK_SIGNALING_PATHWAY | 2.72e-05 | 21 | 40 | 3 | M47792 | |
| Pathway | REACTOME_CD209_DC_SIGN_SIGNALING | 2.72e-05 | 21 | 40 | 3 | M27485 | |
| Pathway | REACTOME_NCAM_SIGNALING_FOR_NEURITE_OUT_GROWTH | 2.93e-05 | 63 | 40 | 4 | M11187 | |
| Pathway | REACTOME_FRS_MEDIATED_FGFR4_SIGNALING | 3.14e-05 | 22 | 40 | 3 | M27522 | |
| Pathway | REACTOME_SHC1_EVENTS_IN_ERBB2_SIGNALING | 3.14e-05 | 22 | 40 | 3 | M26929 | |
| Pathway | REACTOME_FRS_MEDIATED_FGFR1_SIGNALING | 3.60e-05 | 23 | 40 | 3 | M27513 | |
| Pathway | KEGG_MEDICUS_REFERENCE_E2_ER_RAS_ERK_SIGNALING_PATHWAY | 3.60e-05 | 23 | 40 | 3 | M47799 | |
| Pathway | REACTOME_RAS_PROCESSING | 4.11e-05 | 24 | 40 | 3 | M38995 | |
| Pathway | REACTOME_FRS_MEDIATED_FGFR2_SIGNALING | 4.66e-05 | 25 | 40 | 3 | M27517 | |
| Pathway | WP_RELATIONSHIP_BETWEEN_INFLAMMATION_COX2_AND_EGFR | 4.66e-05 | 25 | 40 | 3 | M39794 | |
| Pathway | REACTOME_DOWNSTREAM_SIGNALING_OF_ACTIVATED_FGFR3 | 4.66e-05 | 25 | 40 | 3 | M27520 | |
| Pubmed | KRAS CYFIP1 CSNK1A1 CSNK2A1 SPTBN1 HRAS PPP1R9B MTCL1 SPECC1L PIP4K2C CCDC6 CNOT1 CASK | 2.01e-09 | 963 | 54 | 13 | 28671696 | |
| Pubmed | 3.54e-09 | 3 | 54 | 3 | 25788415 | ||
| Pubmed | Diagnostic Value of RAS Mutations in Indeterminate Thyroid Nodules. | 3.54e-09 | 3 | 54 | 3 | 28116986 | |
| Pubmed | Analysis of k-ras nuclear expression in fibroblasts and mesangial cells. | 3.54e-09 | 3 | 54 | 3 | 20090846 | |
| Pubmed | RAS gene mutations and histomorphometric measurements in oral squamous cell carcinoma. | 3.54e-09 | 3 | 54 | 3 | 37013448 | |
| Pubmed | Comparison of liver oncogenic potential among human RAS isoforms. | 3.54e-09 | 3 | 54 | 3 | 26799184 | |
| Pubmed | 3.54e-09 | 3 | 54 | 3 | 21737741 | ||
| Pubmed | 3.54e-09 | 3 | 54 | 3 | 31906952 | ||
| Pubmed | Partial functional overlap of the three ras genes in mouse embryonic development. | 3.54e-09 | 3 | 54 | 3 | 18059342 | |
| Pubmed | Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. | 3.54e-09 | 3 | 54 | 3 | 23240926 | |
| Pubmed | Mutations of RAS gene family in specimens of bladder cancer. | 3.54e-09 | 3 | 54 | 3 | 19101897 | |
| Pubmed | 3.54e-09 | 3 | 54 | 3 | 25977330 | ||
| Pubmed | 3.54e-09 | 3 | 54 | 3 | 33620658 | ||
| Pubmed | 3.54e-09 | 3 | 54 | 3 | 17943694 | ||
| Pubmed | Absolute Quantification of Endogenous Ras Isoform Abundance. | 3.54e-09 | 3 | 54 | 3 | 26560143 | |
| Pubmed | Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma. | 3.54e-09 | 3 | 54 | 3 | 17712732 | |
| Pubmed | 3.54e-09 | 3 | 54 | 3 | 24222113 | ||
| Pubmed | 3.54e-09 | 3 | 54 | 3 | 28202657 | ||
| Pubmed | Mutational analysis of K-ras and Ras protein expression in larynx squamous cell carcinoma. | 3.54e-09 | 3 | 54 | 3 | 16761621 | |
| Pubmed | Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis. | 3.54e-09 | 3 | 54 | 3 | 22945650 | |
| Pubmed | 3.54e-09 | 3 | 54 | 3 | 22589270 | ||
| Pubmed | 3.54e-09 | 3 | 54 | 3 | 19303097 | ||
| Pubmed | A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation. | 3.54e-09 | 3 | 54 | 3 | 23496764 | |
| Pubmed | Distribution of p21ras during primary palate formation of non-cleft and cleft strains of mice. | 3.54e-09 | 3 | 54 | 3 | 7776260 | |
| Pubmed | 3.54e-09 | 3 | 54 | 3 | 27911734 | ||
| Pubmed | 3.54e-09 | 3 | 54 | 3 | 28630043 | ||
| Pubmed | Absence of oncogenic mutations of RAS family genes in soft tissue sarcomas of 100 Japanese patients. | 3.54e-09 | 3 | 54 | 3 | 20150643 | |
| Pubmed | 3.54e-09 | 3 | 54 | 3 | 20971740 | ||
| Pubmed | Overexpression of wild-type p21Ras plays a prominent role in colorectal cancer. | 3.54e-09 | 3 | 54 | 3 | 28259994 | |
| Pubmed | The variable phenotype and low-risk nature of RAS-positive thyroid nodules. | 3.54e-09 | 3 | 54 | 3 | 26253102 | |
| Pubmed | 3.54e-09 | 3 | 54 | 3 | 16573741 | ||
| Pubmed | 3.54e-09 | 3 | 54 | 3 | 27119512 | ||
| Pubmed | K-ras is an essential gene in the mouse with partial functional overlap with N-ras. | 3.54e-09 | 3 | 54 | 3 | 9334313 | |
| Pubmed | The RAS-Effector Interface: Isoform-Specific Differences in the Effector Binding Regions. | 1.41e-08 | 4 | 54 | 3 | 27936046 | |
| Pubmed | 1.41e-08 | 4 | 54 | 3 | 10085069 | ||
| Pubmed | 1.41e-08 | 4 | 54 | 3 | 38849523 | ||
| Pubmed | Reducing Pericyte-Derived Scarring Promotes Recovery after Spinal Cord Injury. | 1.41e-08 | 4 | 54 | 3 | 29502968 | |
| Pubmed | 1.41e-08 | 4 | 54 | 3 | 34948093 | ||
| Pubmed | 1.41e-08 | 4 | 54 | 3 | 9674433 | ||
| Pubmed | Activated Ras interacts with the Ral guanine nucleotide dissociation stimulator. | 1.41e-08 | 4 | 54 | 3 | 7972015 | |
| Pubmed | 1.41e-08 | 4 | 54 | 3 | 10490827 | ||
| Pubmed | Ras membrane orientation and nanodomain localization generate isoform diversity. | 1.41e-08 | 4 | 54 | 3 | 20080631 | |
| Pubmed | Quantification of spatiotemporal patterns of Ras isoform expression during development. | 1.41e-08 | 4 | 54 | 3 | 28117393 | |
| Pubmed | Tyrosine phosphorylation of RAS by ABL allosterically enhances effector binding. | 1.41e-08 | 4 | 54 | 3 | 25999467 | |
| Pubmed | CYFIP1 MAP1A CADPS CSNK1A1 CSNK2A1 SLC27A1 SPTBN1 PPP1R9B SPECC1L PIP4K2C CNOT1 RPL5 ADD2 CASK | 2.59e-08 | 1431 | 54 | 14 | 37142655 | |
| Pubmed | 3.53e-08 | 5 | 54 | 3 | 9069260 | ||
| Pubmed | 3.53e-08 | 5 | 54 | 3 | 22982107 | ||
| Pubmed | Impeded Nedd4-1-mediated Ras degradation underlies Ras-driven tumorigenesis. | 3.53e-08 | 5 | 54 | 3 | 24746824 | |
| Pubmed | Pericyte-derived fibrotic scarring is conserved across diverse central nervous system lesions. | 3.53e-08 | 5 | 54 | 3 | 34535655 | |
| Pubmed | Activated Ras induces lens epithelial cell hyperplasia but not premature differentiation. | 3.53e-08 | 5 | 54 | 3 | 15558479 | |
| Pubmed | CYFIP1 NRAS EP400 CSNK1A1 CNOT10 CSNK2A1 DHCR24 PARP2 MAP3K20 AIF1L SPECC1L ECT2 AKAP8L CASK | 4.54e-08 | 1497 | 54 | 14 | 31527615 | |
| Pubmed | 4.71e-08 | 127 | 54 | 6 | 30442766 | ||
| Pubmed | CSNK2A1 SPTBN1 EXOC3 PDP2 PPP1R9B PTPN21 CCDC6 CNOT1 AKAP8L ADD2 TPD52 CASK | 5.68e-08 | 1049 | 54 | 12 | 27880917 | |
| Pubmed | Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2. | 6.41e-08 | 25 | 54 | 4 | 8493579 | |
| Pubmed | 7.05e-08 | 6 | 54 | 3 | 21072204 | ||
| Pubmed | 7.05e-08 | 6 | 54 | 3 | 9753431 | ||
| Pubmed | 7.05e-08 | 6 | 54 | 3 | 10882715 | ||
| Pubmed | Glutamate transporter Slc1a3 mediates inter-niche stem cell activation during skin growth. | 7.05e-08 | 6 | 54 | 3 | 29615452 | |
| Pubmed | LZTR1 facilitates polyubiquitination and degradation of RAS-GTPases. | 7.05e-08 | 6 | 54 | 3 | 31337872 | |
| Pubmed | 1.23e-07 | 7 | 54 | 3 | 19487299 | ||
| Pubmed | Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic Transformation. | 1.23e-07 | 7 | 54 | 3 | 35904492 | |
| Pubmed | 1.23e-07 | 7 | 54 | 3 | 20526288 | ||
| Pubmed | 1.23e-07 | 7 | 54 | 3 | 20179099 | ||
| Pubmed | SmgGDS displays differential binding and exchange activity towards different Ras isoforms. | 1.23e-07 | 7 | 54 | 3 | 11948427 | |
| Pubmed | 1.23e-07 | 7 | 54 | 3 | 20860430 | ||
| Pubmed | 1.23e-07 | 7 | 54 | 3 | 20012784 | ||
| Pubmed | 1.23e-07 | 7 | 54 | 3 | 22199277 | ||
| Pubmed | 1.23e-07 | 7 | 54 | 3 | 9690470 | ||
| Pubmed | 1.97e-07 | 8 | 54 | 3 | 15064703 | ||
| Pubmed | Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. | 1.97e-07 | 8 | 54 | 3 | 20150892 | |
| Pubmed | 2.95e-07 | 9 | 54 | 3 | 10783161 | ||
| Pubmed | 2.95e-07 | 9 | 54 | 3 | 9344703 | ||
| Pubmed | 4.21e-07 | 10 | 54 | 3 | 34215617 | ||
| Pubmed | Desmoplakin maintains gap junctions by inhibiting Ras/MAPK and lysosomal degradation of connexin-43. | 4.21e-07 | 10 | 54 | 3 | 29959233 | |
| Pubmed | SHANK proteins limit integrin activation by directly interacting with Rap1 and R-Ras. | 5.79e-07 | 11 | 54 | 3 | 28263956 | |
| Pubmed | MECP2 directly interacts with RNA polymerase II to modulate transcription in human neurons. | MAP1A EP400 CSNK2A1 SPTBN1 USP9Y CNOT1 SNRPF RPL5 AKAP8L ADD2 CASK | 7.06e-07 | 1082 | 54 | 11 | 38697112 |
| Pubmed | 7.71e-07 | 12 | 54 | 3 | 9269777 | ||
| Pubmed | Ras effectors and their role in mitogenesis and oncogenesis. | 7.71e-07 | 12 | 54 | 3 | 9297626 | |
| Pubmed | FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia. | 9.61e-07 | 497 | 54 | 8 | 36774506 | |
| Pubmed | 1.27e-06 | 14 | 54 | 3 | 25359213 | ||
| Pubmed | The Ras branch of small GTPases: Ras family members don't fall far from the tree. | 1.59e-06 | 15 | 54 | 3 | 10712923 | |
| Pubmed | 1.59e-06 | 15 | 54 | 3 | 23831572 | ||
| Pubmed | Novel RFLPs at protooncogene and cancer-related gene loci on mouse chromosomes. | 1.95e-06 | 16 | 54 | 3 | 8095010 | |
| Pubmed | Mechanism of activation of an N-ras gene in the human fibrosarcoma cell line HT1080. | 2.37e-06 | 2 | 54 | 2 | 6086315 | |
| Pubmed | Targeted deletion of the H-ras gene decreases tumor formation in mouse skin carcinogenesis. | 2.37e-06 | 2 | 54 | 2 | 10871846 | |
| Pubmed | 2.37e-06 | 2 | 54 | 2 | 19789336 | ||
| Pubmed | 2.37e-06 | 2 | 54 | 2 | 30860980 | ||
| Pubmed | 2.37e-06 | 2 | 54 | 2 | 16624289 | ||
| Pubmed | 2.37e-06 | 2 | 54 | 2 | 27698462 | ||
| Pubmed | 2.37e-06 | 2 | 54 | 2 | 34117033 | ||
| Pubmed | 2.37e-06 | 2 | 54 | 2 | 22407852 | ||
| Pubmed | Frequent KRAS and HRAS mutations in squamous cell papillomas of the head and neck. | 2.37e-06 | 2 | 54 | 2 | 31960612 | |
| Pubmed | 2.37e-06 | 2 | 54 | 2 | 24018645 | ||
| Pubmed | 2.37e-06 | 2 | 54 | 2 | 6098458 | ||
| Pubmed | 2.37e-06 | 2 | 54 | 2 | 1970154 | ||
| Pubmed | 2.37e-06 | 2 | 54 | 2 | 8280380 | ||
| Pubmed | Combined HRAS and NRAS ablation induces a RASopathy phenotype in mice. | 2.37e-06 | 2 | 54 | 2 | 38886790 | |
| Pubmed | 2.37e-06 | 2 | 54 | 2 | 18769120 | ||
| Pubmed | Wild-type NRas and KRas perform distinct functions during transformation. | 2.37e-06 | 2 | 54 | 2 | 17636015 | |
| Pubmed | 2.37e-06 | 2 | 54 | 2 | 20188103 | ||
| Interaction | LYN interactions | KRAS CYFIP1 NRAS CNOT10 CSNK2A1 SPTBN1 HRAS EXOC3 ZCCHC7 CSNK2A3 RPL5 ADD2 CASK | 3.98e-08 | 720 | 54 | 13 | int:LYN |
| Interaction | NAV2 interactions | 1.02e-07 | 43 | 54 | 5 | int:NAV2 | |
| Interaction | SEPTIN8 interactions | 1.19e-07 | 87 | 54 | 6 | int:SEPTIN8 | |
| Interaction | ADD1 interactions | 3.54e-07 | 171 | 54 | 7 | int:ADD1 | |
| Interaction | HEPH interactions | 3.62e-07 | 6 | 54 | 3 | int:HEPH | |
| Interaction | FLOT1 interactions | 4.55e-07 | 475 | 54 | 10 | int:FLOT1 | |
| Interaction | F11R interactions | 5.58e-07 | 60 | 54 | 5 | int:F11R | |
| Interaction | PLCB1 interactions | 7.14e-07 | 63 | 54 | 5 | int:PLCB1 | |
| Interaction | ACTG1 interactions | KRAS CYFIP1 MAP1A EP400 CSNK1A1 SPTBN1 HRAS PPP1R9B SPECC1L PIP4K2C | 1.04e-06 | 520 | 54 | 10 | int:ACTG1 |
| Interaction | SLC1A4 interactions | 1.20e-06 | 30 | 54 | 4 | int:SLC1A4 | |
| Interaction | CYFIP1 interactions | 1.36e-06 | 303 | 54 | 8 | int:CYFIP1 | |
| Interaction | F2RL3 interactions | 1.51e-06 | 9 | 54 | 3 | int:F2RL3 | |
| Interaction | ATG16L1 interactions | KRAS CYFIP1 MAP1A CSNK1A1 CNOT10 CSNK2A1 EXOC3 PPP1R9B MTCL1 SPECC1L CCDC6 SNRPF RPL5 ADD2 | 1.52e-06 | 1161 | 54 | 14 | int:ATG16L1 |
| Interaction | SPTBN1 interactions | 1.61e-06 | 421 | 54 | 9 | int:SPTBN1 | |
| Interaction | YWHAB interactions | KRAS CYFIP1 CSNK2A1 SPTBN1 MAP3K20 PARD3B PPP1R9B MTCL1 ZCCHC7 PTPN21 PIP4K2C CCDC6 ECT2 | 1.98e-06 | 1014 | 54 | 13 | int:YWHAB |
| Interaction | TRPV2 interactions | 2.15e-06 | 10 | 54 | 3 | int:TRPV2 | |
| Interaction | SLC2A3 interactions | 2.27e-06 | 35 | 54 | 4 | int:SLC2A3 | |
| Interaction | CAPZB interactions | KRAS CNOT10 CSNK2A1 SPTBN1 PPP1R9B AIF1L MTCL1 SPECC1L ECT2 CNOT1 SNRPF RPL5 AKAP8L | 2.89e-06 | 1049 | 54 | 13 | int:CAPZB |
| Interaction | PLEKHO1 interactions | 3.00e-06 | 84 | 54 | 5 | int:PLEKHO1 | |
| Interaction | KIF2A interactions | 3.62e-06 | 242 | 54 | 7 | int:KIF2A | |
| Interaction | TPD52L2 interactions | 3.71e-06 | 156 | 54 | 6 | int:TPD52L2 | |
| Interaction | GTSF1 interactions | 3.93e-06 | 12 | 54 | 3 | int:GTSF1 | |
| Interaction | ABR interactions | 4.33e-06 | 41 | 54 | 4 | int:ABR | |
| Interaction | MAX interactions | 4.60e-06 | 251 | 54 | 7 | int:MAX | |
| Interaction | YWHAH interactions | KRAS LGMN CYFIP1 CSNK1A1 SPTBN1 MAP3K20 PARD3B PPP1R9B MTCL1 SPECC1L PTPN21 CCDC6 ECT2 | 4.95e-06 | 1102 | 54 | 13 | int:YWHAH |
| Interaction | ADD2 interactions | 4.97e-06 | 93 | 54 | 5 | int:ADD2 | |
| Interaction | IPMK interactions | 5.10e-06 | 13 | 54 | 3 | int:IPMK | |
| Interaction | HAGHL interactions | 5.10e-06 | 13 | 54 | 3 | int:HAGHL | |
| Interaction | PPFIBP2 interactions | 5.26e-06 | 43 | 54 | 4 | int:PPFIBP2 | |
| Interaction | FBXO42 interactions | 5.65e-06 | 259 | 54 | 7 | int:FBXO42 | |
| Interaction | TNKS1BP1 interactions | 5.69e-06 | 168 | 54 | 6 | int:TNKS1BP1 | |
| Interaction | PIP4K2B interactions | 5.81e-06 | 96 | 54 | 5 | int:PIP4K2B | |
| Interaction | CADM1 interactions | 6.32e-06 | 45 | 54 | 4 | int:CADM1 | |
| Interaction | ITGB6 interactions | 6.48e-06 | 14 | 54 | 3 | int:ITGB6 | |
| Interaction | SPTBN2 interactions | 6.51e-06 | 172 | 54 | 6 | int:SPTBN2 | |
| Interaction | OCLN interactions | 6.53e-06 | 500 | 54 | 9 | int:OCLN | |
| Interaction | KIF1B interactions | 6.73e-06 | 173 | 54 | 6 | int:KIF1B | |
| Interaction | CDC42 interactions | KRAS CYFIP1 CRIM1 ZSWIM5 SPTBN1 MAP3K20 HRAS EXOC3 RIOK3 PPP1R9B ECT2 CNOT1 SNRPF CASK | 6.97e-06 | 1323 | 54 | 14 | int:CDC42 |
| Interaction | WDR76 interactions | 7.67e-06 | 383 | 54 | 8 | int:WDR76 | |
| Interaction | EPB41L3 interactions | 7.78e-06 | 272 | 54 | 7 | int:EPB41L3 | |
| Interaction | RPS21 interactions | 8.76e-06 | 277 | 54 | 7 | int:RPS21 | |
| Interaction | ROCK2 interactions | 9.00e-06 | 182 | 54 | 6 | int:ROCK2 | |
| Interaction | WDR44 interactions | 9.01e-06 | 105 | 54 | 5 | int:WDR44 | |
| Interaction | ELMOD3 interactions | 9.94e-06 | 16 | 54 | 3 | int:ELMOD3 | |
| Interaction | SAMSN1 interactions | 9.94e-06 | 16 | 54 | 3 | int:SAMSN1 | |
| Interaction | PCDH18 interactions | 9.94e-06 | 16 | 54 | 3 | int:PCDH18 | |
| Interaction | EPB41L1 interactions | 1.05e-05 | 187 | 54 | 6 | int:EPB41L1 | |
| Interaction | FMR1 interactions | 1.14e-05 | 536 | 54 | 9 | int:FMR1 | |
| Interaction | HSP90AB2P interactions | 1.18e-05 | 111 | 54 | 5 | int:HSP90AB2P | |
| Interaction | MINK1 interactions | 1.26e-05 | 193 | 54 | 6 | int:MINK1 | |
| Interaction | KCTD13 interactions | CYFIP1 MAP1A CADPS CSNK1A1 CSNK2A1 SLC27A1 SPTBN1 PPP1R9B SPECC1L PIP4K2C CNOT1 RPL5 ADD2 CASK | 1.27e-05 | 1394 | 54 | 14 | int:KCTD13 |
| Interaction | ATP2B4 interactions | 1.37e-05 | 196 | 54 | 6 | int:ATP2B4 | |
| Interaction | EPB41L5 interactions | 1.41e-05 | 298 | 54 | 7 | int:EPB41L5 | |
| Interaction | KIF23 interactions | KRAS CSNK1A1 CSNK2A1 SPTBN1 PPP1R9B MTCL1 USP9Y ECT2 CSNK2A3 RPL5 AKAP8L ADD2 | 1.41e-05 | 1031 | 54 | 12 | int:KIF23 |
| Interaction | EPB41L2 interactions | 1.44e-05 | 299 | 54 | 7 | int:EPB41L2 | |
| Interaction | MPP1 interactions | 1.59e-05 | 118 | 54 | 5 | int:MPP1 | |
| Interaction | EHBP1L1 interactions | 1.64e-05 | 57 | 54 | 4 | int:EHBP1L1 | |
| Interaction | GYPC interactions | 1.71e-05 | 19 | 54 | 3 | int:GYPC | |
| Interaction | CSNK1A1L interactions | 1.75e-05 | 58 | 54 | 4 | int:CSNK1A1L | |
| Interaction | TIAM1 interactions | 1.77e-05 | 205 | 54 | 6 | int:TIAM1 | |
| Interaction | CAPZA2 interactions | 1.77e-05 | 430 | 54 | 8 | int:CAPZA2 | |
| Interaction | SEPTIN11 interactions | 1.87e-05 | 122 | 54 | 5 | int:SEPTIN11 | |
| Interaction | SLC6A9 interactions | 2.01e-05 | 20 | 54 | 3 | int:SLC6A9 | |
| Interaction | SUSD5 interactions | 2.01e-05 | 20 | 54 | 3 | int:SUSD5 | |
| Interaction | PLCE1 interactions | 2.01e-05 | 20 | 54 | 3 | int:PLCE1 | |
| Interaction | PPP1CC interactions | KRAS CYFIP1 CSNK1A1 SPTBN1 PPP1R9B SPECC1L CCDC6 ECT2 RPL5 CASK | 2.27e-05 | 738 | 54 | 10 | int:PPP1CC |
| Interaction | SEPTIN5 interactions | 2.29e-05 | 62 | 54 | 4 | int:SEPTIN5 | |
| Interaction | TAOK3 interactions | 2.60e-05 | 64 | 54 | 4 | int:TAOK3 | |
| Interaction | DLG3 interactions | 2.63e-05 | 131 | 54 | 5 | int:DLG3 | |
| Interaction | NECTIN1 interactions | 2.70e-05 | 22 | 54 | 3 | int:NECTIN1 | |
| Interaction | SYT7 interactions | 3.10e-05 | 23 | 54 | 3 | int:SYT7 | |
| Interaction | SLC23A2 interactions | 3.10e-05 | 23 | 54 | 3 | int:SLC23A2 | |
| Interaction | BAP1 interactions | KRAS CYFIP1 CSNK2A1 SPTBN1 ELF2 AIF1L CCDC6 CNOT1 SNRPF RPL5 AKAP8L ADD2 TPD52 | 3.25e-05 | 1314 | 54 | 13 | int:BAP1 |
| Interaction | YWHAZ interactions | KRAS CYFIP1 CSNK1A1 SPTBN1 MAP3K20 PARD3B PPP1R9B ZCCHC7 PTPN21 CCDC6 ECT2 SNRPF RPL5 | 3.38e-05 | 1319 | 54 | 13 | int:YWHAZ |
| Interaction | TULP3 interactions | 3.66e-05 | 346 | 54 | 7 | int:TULP3 | |
| Interaction | EXOC1 interactions | 4.01e-05 | 143 | 54 | 5 | int:EXOC1 | |
| Interaction | PIP4P1 interactions | 4.14e-05 | 72 | 54 | 4 | int:PIP4P1 | |
| Interaction | FRMD7 interactions | 4.21e-05 | 4 | 54 | 2 | int:FRMD7 | |
| Interaction | GAL3ST4 interactions | 4.21e-05 | 4 | 54 | 2 | int:GAL3ST4 | |
| Interaction | EPB41 interactions | 4.28e-05 | 145 | 54 | 5 | int:EPB41 | |
| Interaction | DLG1 interactions | 4.29e-05 | 240 | 54 | 6 | int:DLG1 | |
| Interaction | EXOC3 interactions | 5.04e-05 | 150 | 54 | 5 | int:EXOC3 | |
| Interaction | PDLIM4 interactions | 5.08e-05 | 27 | 54 | 3 | int:PDLIM4 | |
| Interaction | RGL2 interactions | 5.68e-05 | 28 | 54 | 3 | int:RGL2 | |
| Interaction | CTNNB1 interactions | KRAS CYFIP1 NRAS EP400 CSNK1A1 CSNK2A1 HRAS PARD3B PPP1R9B SPECC1L ECT2 | 6.19e-05 | 1009 | 54 | 11 | int:CTNNB1 |
| Interaction | RPS20 interactions | 6.20e-05 | 513 | 54 | 8 | int:RPS20 | |
| Interaction | DCUN1D3 interactions | 6.32e-05 | 29 | 54 | 3 | int:DCUN1D3 | |
| Interaction | SLC35A2 interactions | 6.32e-05 | 29 | 54 | 3 | int:SLC35A2 | |
| Interaction | RHOB interactions | CYFIP1 CRIM1 MAP1A CSNK1A1 SPTBN1 EXOC3 PARD3B PIP4K2C ECT2 CASK | 6.78e-05 | 840 | 54 | 10 | int:RHOB |
| Interaction | SLITRK2 interactions | 7.01e-05 | 5 | 54 | 2 | int:SLITRK2 | |
| Interaction | ZNF428 interactions | 7.01e-05 | 30 | 54 | 3 | int:ZNF428 | |
| Interaction | CD276 interactions | 7.01e-05 | 30 | 54 | 3 | int:CD276 | |
| Interaction | DLG2 interactions | 7.23e-05 | 83 | 54 | 4 | int:DLG2 | |
| Interaction | ERBIN interactions | 7.43e-05 | 265 | 54 | 6 | int:ERBIN | |
| Interaction | DLGAP4 interactions | 7.58e-05 | 84 | 54 | 4 | int:DLGAP4 | |
| Interaction | SCRIB interactions | 7.59e-05 | 266 | 54 | 6 | int:SCRIB | |
| Interaction | APC interactions | 7.67e-05 | 389 | 54 | 7 | int:APC | |
| Interaction | MINDY2 interactions | 7.75e-05 | 31 | 54 | 3 | int:MINDY2 | |
| Interaction | DCBLD1 interactions | 7.75e-05 | 31 | 54 | 3 | int:DCBLD1 | |
| Interaction | JAM3 interactions | 7.75e-05 | 31 | 54 | 3 | int:JAM3 | |
| GeneFamily | RAS type GTPase family | 2.40e-05 | 31 | 33 | 3 | 389 | |
| GeneFamily | CCR4-NOT transcription complex | 1.76e-04 | 11 | 33 | 2 | 1023 | |
| GeneFamily | Ataxins|Trinucleotide repeat containing | 9.44e-04 | 25 | 33 | 2 | 775 | |
| GeneFamily | PDZ domain containing | 2.64e-03 | 152 | 33 | 3 | 1220 | |
| Coexpression | TABULA_MURIS_SENIS_MESENTERIC_ADIPOSE_TISSUE_MESENCHYMAL_STEM_CELL_OF_ADIPOSE_AGEING | 1.00e-05 | 685 | 54 | 9 | MM3782 | |
| ToppCell | IIF-Lymphocyte-T_NK-dnT|IIF / Disease, Lineage and Cell Type | 2.97e-05 | 146 | 54 | 4 | d0f361662db5f7be26104346e8431f7e30c5ce3a | |
| ToppCell | facs-Trachea-24m-Mesenchymal-fibroblast-fibroblast_of_trachea-tracheal_fibroblast_l15|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 5.01e-05 | 167 | 54 | 4 | 55c3c68af269fcf40f2b080ae4489523609ad388 | |
| ToppCell | severe-Myeloid-mDC|Myeloid / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs | 5.13e-05 | 168 | 54 | 4 | eff37a92d41624924201372cc09f9eb07b60aec1 | |
| ToppCell | COVID_vent-Lymphocytic-Dendritic-pDC|COVID_vent / Disease condition, Lineage, Cell class and subclass | 5.49e-05 | 171 | 54 | 4 | 779c951d274ecbd1d546ac425d6c8e718623be5a | |
| ToppCell | COVID_vent-Lymphocytic-Dendritic|COVID_vent / Disease condition, Lineage, Cell class and subclass | 5.49e-05 | 171 | 54 | 4 | debbb071d260639b16269c94d172766908325c58 | |
| ToppCell | 10x5'v1-week_12-13-Myeloid_macrophage-stroma-monocytoid_macrophage|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 5.62e-05 | 172 | 54 | 4 | 9befd44bce43eb5dc1fe3d2e44608f442cf74a47 | |
| ToppCell | Mild/Remission-B_naive-8|World / disease group and sub_cluster of B and Plasma cells(res = 0.5) | 5.75e-05 | 173 | 54 | 4 | 694d02c4d2dc2de4b344544f9124fec40fcf7d8f | |
| ToppCell | Control-Lymphoid-pDC|Control / Condition, Lineage and Cell class | 6.14e-05 | 176 | 54 | 4 | 5de16ff65476bde8b23322a44e11412e14f1bafe | |
| ToppCell | LPS-antiTNF-Epithelial_alveolar-Mes-like-AT1_Progenitor|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 6.28e-05 | 177 | 54 | 4 | 164ffbbf798defa3728197deb1a14b661490e525 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_convalescent_d42-56-Myeloid-Dendritic-plasmacytoid_dendritic_cell|Severe-critical_convalescent_d42-56 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 6.56e-05 | 179 | 54 | 4 | 124da6f882968dc0d05f3edd8f3b4d61617cc214 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_convalescent_d42-56-Myeloid-Dendritic-plasmacytoid_dendritic_cell-DC_c4-LILRA4|Severe-critical_convalescent_d42-56 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 6.56e-05 | 179 | 54 | 4 | edc5ef693dc4e7ea70717b77fb908fc784dce3a2 | |
| ToppCell | 10x5'-lymph-node_spleen-Hematopoietic_progenitors-Progenitor_pre-Lymphocytic-T|lymph-node_spleen / Manually curated celltypes from each tissue | 7.61e-05 | 186 | 54 | 4 | 17eec1efad1f5e9ced1eb6bc9eb5dd7ded789c61 | |
| ToppCell | 10x5'v1-week_14-16-Hematopoietic-HSC/MPP_and_pro-ELP|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 8.10e-05 | 189 | 54 | 4 | 46c3f3dff71e7131a5ad1cd3b68709051a474c3c | |
| ToppCell | PND01-03-samps-Mesenchymal-Matrix_fibroblast-MatrixFB-A|PND01-03-samps / Age Group, Lineage, Cell class and subclass | 8.43e-05 | 191 | 54 | 4 | e7c605b56934d1383237c1f946dbccef25d91368 | |
| ToppCell | facs-Thymus-Flowthrough-3m|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.60e-05 | 192 | 54 | 4 | 7a0ef1702d6538e5611cfdc633d8558f9523845c | |
| ToppCell | facs-Thymus-Flowthrough-3m-Lymphocytic|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.60e-05 | 192 | 54 | 4 | 05043fb75319b64f5ed7aee6a232309dcae891b8 | |
| ToppCell | PND01-03-samps-Mesenchymal|PND01-03-samps / Age Group, Lineage, Cell class and subclass | 8.95e-05 | 194 | 54 | 4 | 4f9bd0ded0dde1df885850714f29e73e992539a5 | |
| ToppCell | Mild/Remission-B_naive-8|Mild/Remission / disease group and sub_cluster of B and Plasma cells(res = 0.5) | 9.13e-05 | 195 | 54 | 4 | 0a3221e4d1fa31a35868bdda0f0cc873c233b407 | |
| ToppCell | droplet-Tongue-TONGUE|Tongue / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 9.32e-05 | 196 | 54 | 4 | 44a30b1a5f3d8c845e5f3bd17d8102a7449f555b | |
| ToppCell | droplet-Tongue-TONGUE-1m|Tongue / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 9.32e-05 | 196 | 54 | 4 | 9935bdb10789e8cfc922dca526ca3bf8317fe270 | |
| ToppCell | droplet-Tongue-TONGUE-1m-Epithelial|Tongue / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 9.32e-05 | 196 | 54 | 4 | a85f5f1e6acc798e9e02b1a21e0ffe87a323c333 | |
| ToppCell | PND01-03-samps-Mesenchymal-Matrix_fibroblast|PND01-03-samps / Age Group, Lineage, Cell class and subclass | 9.32e-05 | 196 | 54 | 4 | 54f4cf778f95a9ff662e5c7520916a25e605bf95 | |
| ToppCell | 10x5'v1-week_14-16-Lymphocytic_B|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 9.50e-05 | 197 | 54 | 4 | 31dfd9842410b5c629f39b5130233995dceb0aef | |
| ToppCell | 10x5'v1-week_14-16-Lymphocytic_B-B_lineage-pre_B_progenitor|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 9.50e-05 | 197 | 54 | 4 | 78122e1fb80e0ac3084dd4f7c551996330a701df | |
| ToppCell | 10x5'v1-week_14-16-Lymphocytic_B-B_lineage|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 9.50e-05 | 197 | 54 | 4 | 7290f05d0b8465637420119941bcbf2fae44a7e4 | |
| ToppCell | 10x3'2.3-week_17-19-Lymphocytic_B|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 9.69e-05 | 198 | 54 | 4 | 5f465cf5c7493e32d9afe9e9d05757d0a95acc33 | |
| ToppCell | Control_saline-Mesenchymal_fibroblastic-Fibroblasts-Activated_MatrixFB|Control_saline / Treatment groups by lineage, cell group, cell type | 9.69e-05 | 198 | 54 | 4 | 0c4d2c68a42f8a9e964e2dd28092fe75f5216834 | |
| ToppCell | 10x3'2.3-week_17-19-Lymphocytic_B-B_lineage|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 9.69e-05 | 198 | 54 | 4 | 77ce3fe1ab161c0faf8987e73a64ab61294b9255 | |
| ToppCell | COVID-19_Severe-cDC|World / disease group, cell group and cell class | 9.69e-05 | 198 | 54 | 4 | c452334249f047265ae89dcabe7de446d968cae6 | |
| ToppCell | saliva-Severe-critical_progression_d12-22_no-steroids-Myeloid-Dendritic|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 9.88e-05 | 199 | 54 | 4 | 8e87ba32fcc1d45be73098e5baa6c9c6369b97df | |
| ToppCell | saliva-Severe-critical_progression_d12-22_no-steroids-Myeloid-Dendritic-conventional_dendritic_cell|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 9.88e-05 | 199 | 54 | 4 | 15d7b2479a1426dd8f38ef70225ce07f48f320b2 | |
| ToppCell | saliva-Severe-critical_progression_d12-22_no-steroids-Myeloid-Dendritic-conventional_dendritic_cell-DC_c2-CD1C|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.01e-04 | 200 | 54 | 4 | 5a3b04aaad9562636aa34750d6025e0fe0f9b2ba | |
| ToppCell | Sepsis-Bac-SEP-Lymphocyte-B-B_naive|Bac-SEP / Disease, condition lineage and cell class | 1.01e-04 | 200 | 54 | 4 | d377227314a4684d1bad15a13d87b1fa74b998f1 | |
| ToppCell | MS-IIF-Lymphocyte-T/NK-dn_T|IIF / Disease, condition lineage and cell class | 1.01e-04 | 200 | 54 | 4 | c34fff02992cba6bcc2308019cb00b94e1227300 | |
| Drug | L 744832 | 5.04e-08 | 4 | 54 | 3 | ctd:C096898 | |
| Drug | AC1L32OA | 1.05e-06 | 9 | 54 | 3 | CID000107745 | |
| Drug | isoprene | 5.52e-06 | 2 | 54 | 2 | ctd:C005059 | |
| Drug | Prostaglandin E1; Up 200; 10uM; MCF7; HT_HG-U133A | 7.11e-06 | 197 | 54 | 6 | 6576_UP | |
| Drug | Tetranitromethane | 1.65e-05 | 3 | 54 | 2 | ctd:D013774 | |
| Drug | GGTI 2147 | 1.65e-05 | 3 | 54 | 2 | ctd:C466792 | |
| Drug | S-ethylcysteine | 3.96e-05 | 28 | 54 | 3 | CID000030993 | |
| Disease | Nevus sebaceous | 5.16e-09 | 3 | 52 | 3 | C3854181 | |
| Disease | Inflammatory linear verrucous epidermal nevus | 5.16e-09 | 3 | 52 | 3 | C0473574 | |
| Disease | SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME | 5.16e-09 | 3 | 52 | 3 | 163200 | |
| Disease | Verrucous epidermal nevus | 5.16e-09 | 3 | 52 | 3 | C0362030 | |
| Disease | linear nevus sebaceous syndrome (is_implicated_in) | 5.16e-09 | 3 | 52 | 3 | DOID:0111530 (is_implicated_in) | |
| Disease | Noonan syndrome 3 (implicated_via_orthology) | 5.16e-09 | 3 | 52 | 3 | DOID:0060581 (implicated_via_orthology) | |
| Disease | Nevus Sebaceus of Jadassohn | 5.16e-09 | 3 | 52 | 3 | C4552097 | |
| Disease | Organoid Nevus Phakomatosis | 5.16e-09 | 3 | 52 | 3 | C0265329 | |
| Disease | Linear nevus sebaceous syndrome | 5.16e-09 | 3 | 52 | 3 | cv:C4552097 | |
| Disease | Linear Verrucous Epidermal Nevus | 5.16e-09 | 3 | 52 | 3 | C3179502 | |
| Disease | cervical cancer (implicated_via_orthology) | 5.16e-09 | 3 | 52 | 3 | DOID:4362 (implicated_via_orthology) | |
| Disease | NEVUS, EPIDERMAL (disorder) | 5.15e-08 | 5 | 52 | 3 | C0334082 | |
| Disease | Follicular thyroid carcinoma | 5.15e-08 | 5 | 52 | 3 | C0206682 | |
| Disease | Hemimegalencephaly | 1.03e-07 | 6 | 52 | 3 | C0431391 | |
| Disease | RASopathy (implicated_via_orthology) | 4.30e-07 | 9 | 52 | 3 | DOID:0080690 (implicated_via_orthology) | |
| Disease | heart disease (implicated_via_orthology) | 6.05e-07 | 38 | 52 | 4 | DOID:114 (implicated_via_orthology) | |
| Disease | Turner Syndrome, Male | 8.43e-07 | 11 | 52 | 3 | C0041409 | |
| Disease | Female Pseudo-Turner Syndrome | 8.43e-07 | 11 | 52 | 3 | C1527404 | |
| Disease | Noonan Syndrome 1 | 8.43e-07 | 11 | 52 | 3 | C4551602 | |
| Disease | kidney cancer (implicated_via_orthology) | 8.43e-07 | 11 | 52 | 3 | DOID:263 (implicated_via_orthology) | |
| Disease | whole-brain volume, Alzheimer's disease biomarker measurement | 1.85e-06 | 14 | 52 | 3 | EFO_0005089, EFO_0006514 | |
| Disease | RASopathy | 2.31e-06 | 15 | 52 | 3 | cv:C5555857 | |
| Disease | Melanocytic nevus | 3.05e-06 | 2 | 52 | 2 | cv:C0027962 | |
| Disease | RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER | 3.05e-06 | 2 | 52 | 2 | C2674723 | |
| Disease | RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER | 3.05e-06 | 2 | 52 | 2 | 614470 | |
| Disease | Autoimmune lymphoproliferative syndrome type 4 | 3.05e-06 | 2 | 52 | 2 | cv:C2674723 | |
| Disease | autoimmune lymphoproliferative syndrome type 4 (is_implicated_in) | 3.05e-06 | 2 | 52 | 2 | DOID:0110117 (is_implicated_in) | |
| Disease | large congenital melanocytic nevus (is_implicated_in) | 3.05e-06 | 2 | 52 | 2 | DOID:0111359 (is_implicated_in) | |
| Disease | MELANOCYTIC NEVUS SYNDROME, CONGENITAL | 3.05e-06 | 2 | 52 | 2 | 137550 | |
| Disease | Large congenital melanocytic nevus | 3.05e-06 | 2 | 52 | 2 | cv:C1842036 | |
| Disease | Noonan-Like Syndrome With Loose Anagen Hair | 4.90e-06 | 19 | 52 | 3 | C3501846 | |
| Disease | Costello syndrome (disorder) | 4.90e-06 | 19 | 52 | 3 | C0587248 | |
| Disease | Noonan syndrome-like disorder with loose anagen hair | 4.90e-06 | 19 | 52 | 3 | C1843181 | |
| Disease | leukemia (implicated_via_orthology) | 4.90e-06 | 19 | 52 | 3 | DOID:1240 (implicated_via_orthology) | |
| Disease | Cardio-facio-cutaneous syndrome | 4.90e-06 | 19 | 52 | 3 | C1275081 | |
| Disease | LEOPARD Syndrome | 7.76e-06 | 22 | 52 | 3 | C0175704 | |
| Disease | GIANT PIGMENTED HAIRY NEVUS | 9.13e-06 | 3 | 52 | 2 | C1842036 | |
| Disease | Noonan Syndrome | 1.02e-05 | 24 | 52 | 3 | C0028326 | |
| Disease | Papillary thyroid carcinoma | 1.64e-05 | 86 | 52 | 4 | C0238463 | |
| Disease | Nevus, Keratinocytic, Nonepidermolytic | 1.82e-05 | 4 | 52 | 2 | C4011754 | |
| Disease | BLADDER CANCER | 1.82e-05 | 4 | 52 | 2 | 109800 | |
| Disease | Epidermal nevus | 1.82e-05 | 4 | 52 | 2 | cv:C0334082 | |
| Disease | Malignant tumor of urinary bladder | 1.82e-05 | 4 | 52 | 2 | cv:C0005684 | |
| Disease | NEVUS, EPIDERMAL | 1.82e-05 | 4 | 52 | 2 | 162900 | |
| Disease | Thyroid cancer, nonmedullary, 2 | 1.82e-05 | 4 | 52 | 2 | cv:C4225426 | |
| Disease | Malignant neoplasm of penis | 1.82e-05 | 4 | 52 | 2 | C0153601 | |
| Disease | Penile Neoplasms | 1.82e-05 | 4 | 52 | 2 | C0030849 | |
| Disease | Malignant tumor of cervix | 1.82e-05 | 4 | 52 | 2 | C0007847 | |
| Disease | epidermal nevus (is_implicated_in) | 1.82e-05 | 4 | 52 | 2 | DOID:0111162 (is_implicated_in) | |
| Disease | THYROID CANCER, NONMEDULLARY, 2 | 1.82e-05 | 4 | 52 | 2 | 188470 | |
| Disease | hypertrophic cardiomyopathy (implicated_via_orthology) | 1.83e-05 | 29 | 52 | 3 | DOID:11984 (implicated_via_orthology) | |
| Disease | colorectal cancer (implicated_via_orthology) | 2.03e-05 | 30 | 52 | 3 | DOID:9256 (implicated_via_orthology) | |
| Disease | intestinal cancer (implicated_via_orthology) | 2.47e-05 | 32 | 52 | 3 | DOID:10155 (implicated_via_orthology) | |
| Disease | prostate cancer (implicated_via_orthology) | 2.71e-05 | 33 | 52 | 3 | DOID:10283 (implicated_via_orthology) | |
| Disease | THYROID CANCER, NONMEDULLARY, 2 | 3.04e-05 | 5 | 52 | 2 | C4225426 | |
| Disease | Malignant neoplasm of thyroid | 3.04e-05 | 5 | 52 | 2 | C0007115 | |
| Disease | Cetuximab response | 3.04e-05 | 5 | 52 | 2 | cv:CN077967 | |
| Disease | Cervix carcinoma | 3.04e-05 | 5 | 52 | 2 | C0302592 | |
| Disease | Panitumumab response | 3.04e-05 | 5 | 52 | 2 | cv:CN077999 | |
| Disease | Thyroid Neoplasm | 3.84e-05 | 37 | 52 | 3 | C0040136 | |
| Disease | dietary heme iron intake measurement, type 2 diabetes mellitus | 4.55e-05 | 6 | 52 | 2 | EFO_0008355, MONDO_0005148 | |
| Disease | Autoimmune lymphoproliferative syndrome | 4.55e-05 | 6 | 52 | 2 | cv:CN301239 | |
| Disease | Carcinoma in situ of uterine cervix | 4.55e-05 | 6 | 52 | 2 | C0851140 | |
| Disease | level of Phosphatidylcholine (18:2_0:0) in blood serum | 4.55e-05 | 6 | 52 | 2 | OBA_2045105 | |
| Disease | seminoma (is_implicated_in) | 4.55e-05 | 6 | 52 | 2 | DOID:4440 (is_implicated_in) | |
| Disease | Pleocytosis | 4.55e-05 | 6 | 52 | 2 | C0151857 | |
| Disease | Leukocytosis | 4.55e-05 | 6 | 52 | 2 | C0023518 | |
| Disease | Thyroid cancer, follicular | 6.36e-05 | 7 | 52 | 2 | C2931367 | |
| Disease | high grade glioma (implicated_via_orthology) | 6.50e-05 | 44 | 52 | 3 | DOID:3070 (implicated_via_orthology) | |
| Disease | Thyroid carcinoma | 6.50e-05 | 44 | 52 | 3 | C0549473 | |
| Disease | Neuroblastoma | 7.92e-05 | 47 | 52 | 3 | C0027819 | |
| Disease | Alzheimer's disease biomarker measurement, brain volume measurement | 8.47e-05 | 8 | 52 | 2 | EFO_0006514, EFO_0006930 | |
| Disease | Noonan syndrome | 1.09e-04 | 9 | 52 | 2 | cv:C0028326 | |
| Disease | 1-palmitoyl-2-arachidonoyl-GPE (16:0/20:4) measurement | 1.09e-04 | 9 | 52 | 2 | EFO_0800409 | |
| Disease | thyroid gland papillary carcinoma (is_implicated_in) | 1.36e-04 | 10 | 52 | 2 | DOID:3969 (is_implicated_in) | |
| Disease | entorhinal cortical volume, Alzheimer's disease biomarker measurement | 1.66e-04 | 11 | 52 | 2 | EFO_0005092, EFO_0006514 | |
| Disease | metabolite measurement, body weight gain | 1.99e-04 | 12 | 52 | 2 | EFO_0004566, EFO_0004725 | |
| Disease | carcinoma (implicated_via_orthology) | 1.99e-04 | 64 | 52 | 3 | DOID:305 (implicated_via_orthology) | |
| Disease | Neoplasms, Experimental | 2.18e-04 | 66 | 52 | 3 | C0027659 | |
| Disease | middle temporal gyrus volume measurement, Alzheimer's disease biomarker measurement | 2.35e-04 | 13 | 52 | 2 | EFO_0006514, EFO_0010316 | |
| Disease | cardiomyopathy (implicated_via_orthology) | 2.71e-04 | 71 | 52 | 3 | DOID:0050700 (implicated_via_orthology) | |
| Disease | dysmenorrheic pain measurement | 3.60e-04 | 16 | 52 | 2 | EFO_0007889 | |
| Disease | Hemangiosarcoma | 4.58e-04 | 18 | 52 | 2 | C0018923 | |
| Disease | level of Phosphatidylethanolamine (18:0_20:4) in blood serum | 5.11e-04 | 19 | 52 | 2 | OBA_2045140 | |
| Disease | Juvenile Myelomonocytic Leukemia | 5.11e-04 | 19 | 52 | 2 | C0349639 | |
| Disease | Adenocarcinoma of large intestine | 6.57e-04 | 96 | 52 | 3 | C1319315 | |
| Disease | Splenomegaly | 6.88e-04 | 22 | 52 | 2 | C0038002 | |
| Disease | Carcinoma of lung | 7.53e-04 | 23 | 52 | 2 | C0684249 | |
| Disease | Neoplasm of the genitourinary tract | 8.20e-04 | 24 | 52 | 2 | cv:C0042065 | |
| Disease | glioblastoma (is_implicated_in) | 8.20e-04 | 24 | 52 | 2 | DOID:3068 (is_implicated_in) | |
| Disease | paracentral lobule volume measurement | 8.90e-04 | 25 | 52 | 2 | EFO_0010317 | |
| Disease | Alzheimer's disease (is_marker_for) | 1.10e-03 | 257 | 52 | 4 | DOID:10652 (is_marker_for) | |
| Disease | cancer (implicated_via_orthology) | 1.28e-03 | 268 | 52 | 4 | DOID:162 (implicated_via_orthology) | |
| Disease | Adult T-Cell Lymphoma/Leukemia | 1.37e-03 | 31 | 52 | 2 | C0023493 | |
| Disease | Squamous cell carcinoma | 1.38e-03 | 124 | 52 | 3 | C0007137 | |
| Disease | Malignant Neoplasms | 1.51e-03 | 128 | 52 | 3 | C0006826 | |
| Disease | Cardiomyopathies | 1.58e-03 | 130 | 52 | 3 | C0878544 | |
| Disease | Thyroid Gland Follicular Adenoma | 1.75e-03 | 35 | 52 | 2 | C0151468 | |
| Disease | Uterine Cervical Neoplasm | 1.75e-03 | 35 | 52 | 2 | C0007873 | |
| Disease | late-onset Alzheimers disease | 1.75e-03 | 292 | 52 | 4 | EFO_1001870 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| YMEFDLNNEGEIDLM | 56 | Q9BQI0 | |
| MEYVYEDVDGQTEVM | 2231 | Q96L91 | |
| YGRYGDNVEEMDWMV | 286 | Q5FYA8 | |
| YSMQEMYDVVSGVED | 86 | Q9H8M1 | |
| GRYMELEQRYMDLAE | 486 | Q69YQ0 | |
| MDDERYFNEMSAQGL | 331 | Q16204 | |
| RSGYDYSELDPEMEM | 141 | Q9ULX6 | |
| YSELDPEMEMAYEGQ | 146 | Q9ULX6 | |
| QEEYSAMRDQYMRTG | 61 | P01112 | |
| QEEYSAMRDQYMRTG | 61 | P01116 | |
| QEEYSAMRDQYMRTG | 61 | P01111 | |
| EMGAYGYEDLQQRVM | 166 | O95897 | |
| IQMDARAGETMYLYE | 341 | Q9H8V3 | |
| MEEMRDSYLEEDVYQ | 361 | Q9Y4B5 | |
| YDMLQMDYATNTQDE | 201 | Q9UGN5 | |
| MADEAFMNAVQSYYE | 171 | Q9ULU8 | |
| EMLEEGQEYAVMLYT | 71 | Q7L576 | |
| VYDMDDDEMDPNYAR | 941 | Q8TEW8 | |
| MMQDISNNEYLEYGS | 796 | O14936 | |
| DERSFQYADIYEQMM | 1961 | P78559 | |
| NYFGEDDMYMDFEEV | 751 | Q2LD37 | |
| QAMVLEMFREEDYYN | 576 | Q86UT6 | |
| LYMQEVERMDGYGEE | 206 | Q16825 | |
| NNEYGEMEAERLAAM | 481 | Q9P2J9 | |
| ELLVDYQMYDYSLDM | 201 | Q8NEV1 | |
| GFQMLYADCYMNREE | 466 | Q15392 | |
| QMIVRRYANEDGDMD | 191 | Q96L46 | |
| VEYYDGDMFRMDNCR | 341 | Q9NZV1 | |
| ELLVDYQMYDYSLDM | 201 | P68400 | |
| YDDETYMMQDVAEEQ | 56 | Q15723 | |
| YDYINSNRSEEMDMD | 91 | Q9NYL2 | |
| MDLECSRDGLMYEQY | 146 | O60645 | |
| LGMYRVSVDNEDSYM | 186 | Q8TBX8 | |
| TAEQLMEYLGDYMLD | 291 | Q8NBR6 | |
| RDDMESLGYVLMYFN | 201 | P48729 | |
| GQNVADYMRYLMEED | 201 | P46777 | |
| QGYFEQEDDMMEVPY | 2631 | Q4LDE5 | |
| IDNYEEDYQKMRDMG | 1111 | Q01082 | |
| LLVGDMAYYDFNGEM | 251 | P35612 | |
| MAYYDFNGEMEQEAD | 256 | P35612 | |
| MRMEDEDYNTSISYG | 1 | Q99788 | |
| MDGLDDVENSMLYYN | 101 | Q9H9A5 | |
| AMAEWYMRGEQYDQA | 541 | A5YKK6 | |
| AQMLQMEYDREYDAQ | 81 | O14730 | |
| RLNDDGYLEMSDMNE | 621 | Q9P217 | |
| MDELGYMYFRDRSGD | 496 | Q6PCB7 | |
| DAMLDTYDLVYEQAM | 121 | Q96QS1 | |
| MESMLRYEVYGGENE | 601 | Q6ZVD7 | |
| MLEMRDVYMEEDVYQ | 1 | O94964 | |
| QPEDEAMYYCAMGAR | 106 | P12018 | |
| YILFYEQMDMIDEDD | 1951 | O00507 | |
| VDGYMNMQLANTEEY | 36 | P62306 | |
| MMFGGYETIEAYEDD | 1 | Q8N3Z6 | |
| MDCREMDLYEDYQSP | 1 | P55327 | |
| DEEDYVEMKEQMYQD | 61 | Q9H7L9 | |
| IVVMMYDDIAYSEDN | 66 | Q99538 | |
| EYMAYGDLNEFLRSM | 656 | O15146 | |
| REMMEQRYAQYGEDD | 606 | Q96SB3 |